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Abstract 
Death from ischaemic heart disease (IHD) remains the most common cause 
of death worldwide, and is also a significant cause of morbidity. Coronary 
artery bypass graft (CABG) surgery is performed in a significant number of 
IHD patients that meet certain clinical and angiographic criteria or are 
unsuitable for percutaneous coronary intervention. Increasingly higher risk 
surgeries are taking place, as the population survives to become more aged 
with well-managed co-morbidities. As such, the myocardium is at risk of peri-
operative myocardial injury (PMI) during CABG surgery, the presence of 
which impacts on clinical outcomes. There are a number of strategies already 
in place to protect the myocardium during CABG surgery including therapeutic 
hypothermia, and the use of cardioplegic solutions, but there is a need to 
increase cardioprotection especially in higher-risk patients.  
In this regard, remote ischaemic conditioning (RIPC) is a promising, yet 
simple and cheap, non-invasive intervention, which shows huge promise in 
reducing PMI during CABG surgery. RIPC involves the serial inflations and 
deflations of a blood pressure cuff to the upper and/or lower limbs to induce 
brief cycles of ischaemia and reperfusion to the skeletal muscle. Despite the 
promise, clinical studies have produced variable results RIPC in the setting of 
CABG surgery, with confounding factors such as co-morbidities (age and 
diabetes) and comedications (propofol and glyceryl trinitrate) being proposed 
to interfere with the cardioprotective effect.  
In two separate clinical studies of adult patients undergoing CABG 
surgery, we investigated the effect of diabetes and glyceryl trinitrate (GTN) on 
the cardioprotective effect elicited by RIPC. We used an intensified RIPC 
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protocol comprising 3 cycles of simultaneous inflation and deflation of two 
cuffs – one placed on the upper arm and the other on the thigh. The primary 
outcome measures of both clinical studies, was the extent of peri-operative 
myocardial injury (PMI), as evidenced by the 72 hours serum Troponin T 
area-under-the-curve. Secondary outcomes measures included the incidence 
of post-operative atrial fibrillation, acute kidney injury, inotrope score and 
length of intensive care and hospital stay. In the diabetic study, we found that 
RIPC significantly reduced the extent of PMI, whereas in the GTN study, 
RIPC resulted in only a non-significant reduction in PMI, when compared to 
control. There were no differences in the secondary outcome measurements 
with RIPC versis control in either study. In conclusion, we have demonstrated 
that intensifying the RIPC stimulus can overcome the confounding effects of 
diabetes and GTN on RIPC cardioprotection in patients undergoing CABG 
surgery.  
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Chapter 1: Introduction 
1.1 An overview of coronary artery disease and valvular heart disease 
and cardiac surgery 
 
1.1.1 Coronary artery disease – a perspective. 
Coronary artery disease mortality has declined significantly over the last four 
decades in developed countries, although it remains the most common cause 
of death worldwide (1). In the United Kingdom, there are 82,000 deaths a year 
from coronary artery disease. In addition, there is a significant impact on 
morbidity from coronary artery disease with 2 million sufferers of angina in the 
UK, and some 750,000 people with heart failure. The economic burden from 
this is vast, with £3.2 billion spent per year in the UK on ischaemic heart 
disease (2). 
 
1.2 Revascularisation in coronary artery disease 
1.2.1 Coronary artery bypass graft surgery 
The main indications for revascularisation in coronary artery disease are to 
improve symptoms in patients with angina on maximal medical therapy, and 
to improve prognosis in patients with a significant burden of ischaemia (3). 
The Class 1 indications of the AHA/ACC guidelines for coronary artery bypass 
graft (CABG) surgery include the following (4, 5): 
 Left main coronary artery stenosis >50% 
 Proximal left anterior descending artery (LAD) and proximal 
circumflex stenosis >70% 
 3-vessel disease in those with stable or mild angina or even 
asymptomatic disease 
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 3-vessel disease with proximal LAD stenosis in patients with poor left 
ventricular (LV) function 
 A large area of viable myocardium in a high-risk area in patients with 
stable angina and 1 to 2 vessel coronary artery disease 
 Proximal LAD stenosis >70% with either LV ejection fraction <50% or 
demonstrable ischaemia on non-invasive testing 
Rarely CABG surgery, may be performed as an emergency in the context of 
an ST-segment elevation myocardial infarction (STEMI), in cases where it has 
not been possible to revascularise with primary percutaneous coronary 
intervention (PCI), and despite medical therapy there is ongoing pain and 
ischaemia threatening a significant area of myocardium. Surgery should be 
performed in the initial 4 hours from presentation before myocardium 
becomes necrotic. After this window, there is an inverse relationship between 
the time elapsed from STEMI and surgical mortality. A waiting period of 3 to 7 
days appears to be the optimal time for outcome in the absence of symptoms 
and haemodynamic instability (6). 
Initially CABG was the treatment of choice for coronary artery disease but 
over the last two decades, PCI has challenged CABG especially with the 
advent of drug eluting stents. The relative efficacies of both treatment 
strategies have been hotly debated but in-roads have been made providing 
guidance for clinicians with the publication of the SYNTAX (7) and FREEDOM 
(8) trials, and analysis of several large registries. The SYNTAX trial 
randomised 1800 patients with 3 vessel coronary artery disease and left main 
stenosis (LMS) stenosis to PCI or CABG. A SYNTAX score was calculated 
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using angiographic appearances to the effect that the higher the score the 
more severe and complex the disease (9). Intermediate and high scoring 
patients (>18 and >27, respectively) were associated with increasing cardiac 
mortality, major adverse cardiac events, and were ultimately found to be best 
served by CABG as opposed to PCI (10). The FREEDOM trial showed that 
patients with diabetes and multivessel coronary artery disease treated with 
CABG surgery had significantly lower rates of death from any cause, nonfatal 
MI, or nonfatal stroke when compared with diabetic patients treated with PCI. 
When the SYNTAX score was applied to these patients the absolute 
difference in the primary end-point persisted between PCI and surgery with 
low, intermediate, and high SYNTAX scores, thus implying that surgery 
conferred a benefit in all diabetic patients regardless of the severity or 
complexity of coronary disease. It is well recognised, that the rate of fatal 
coronary heart disease is higher in patients with diabetes than in those 
without (11) and so from this it can be inferred that as seen in the SYNTAX 
trial CABG is most beneficial in higher risk patients, making those that have 
diabetes qualify automatically regardless of other risk factors and coronary 
anatomy.   
1.2.2 Valvular heart surgery 
Although valvular heart surgery, is less frequently performed than CABG 
surgery, it is still common despite the decline in rheumatic heart disease in 
developed countries. Other than in developing countries rheumatic heart 
disease is now rare, and although some glory goes to the ready availability of 
penicillin, the truth is that better hygiene and living conditions have resulted in 
reduced transmission of Group A streptococci (12). This means that valvular 
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heart disease is now largely a degenerative disease of the elderly with aortic 
stenosis and mitral regurgitation being the forerunners and aortic regurgitation 
and mitral stenosis trailing behind but in equal frequency (13).This means that 
the majority of patients requiring valvular heart surgery will have comorbidities 
contributing to an increased operative risk.  
 
1.2.3 Cardiac surgeries are now higher risk 
In essence, cardiac surgery is increasingly being performed in higher risk 
patients. This is due to increased life expectancy resulting in an older cohort 
of patients with more comorbidities (14). Similarly, valvular heart disease has 
a more elderly patient demographic.  In addition, higher risk patients are being 
selected out for CABG over PCI through the use of scoring systems. These 
risks need to be offset and this can be done by the development of existing or 
new therapeutic strategies that improve cardioprotection. 
 
1.3 Perioperative myocardial injury and infarction 
1.3.1 Defining perioperative myocardial injury 
Up until the 1990s, there was no consensus on the definition of perioperative 
myocardial infarction and its significance on long-term prognosis was debated 
(15). Despite a lack of evidence, a joint European and American task force put 
forward an expert consensus in 2007 that biomarker values >x5 of the 99th 
percentile of the normal reference range during the first 72 hrs following 
CABG with new pathological Q-waves or new left bundle branch block 
(LBBB), angiographically documented new graft or native coronary artery 
occlusion, or imaging that demonstrates new loss of viable myocardium, 
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should be considered as diagnostic of CABG-related myocardial infarction or 
Type 5 MI (16). It is now believed that 2 to 15% of patients undergoing cardiac 
surgery develop postoperative myocardial infarction resulting in decreased 
short and long-term survival (17). Obviously, the degree of myocardial injury 
that is encountered after surgery lies on a spectrum with some patients having 
lesser insults not fulfilling the definition criterion for myocardial infarction. This 
is illustrated by studies showing prognostically significant low-level troponin 
elevations in high-risk cardiac patients using current highly sensitive troponin 
assays (18).  
 
1.3.2 Causes of perioperative myocardial injury 
The triggers for perioperative myocardial injury are many. Perhaps the most 
common and important of these triggers is myocardial oxygen supply and 
demand mismatch, with tachycardia being the most common mechanism of 
this imbalance (19). The preoperative causes of tachycardia are many and 
include light level of anesthesia, endotracheal intubation and extubation, 
hypovolaemia, fever, anaemia, congestive heart failure, and postoperative 
pain.  Other contributors to inadequate oxygen supply include hypertension, 
hypotension, blood loss, drugs, systemic vasodilatation, and left ventricular 
hypertrophy. Inadequate ventilation may also account for mismatch with 
hypoxaemia and hypercarbia aggravating any resultant ischaemia. 
 
As well as the direct trauma of surgery, there are also extreme stresses 
involved in inducing a hypercoaguable state. These include pain, anaesthesia, 
analgesia, bleeding and hypothermia. The stress state results in increased 
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catecholamines and cortisol, which in turn results in increases in heart rate, 
blood pressure, relative insulin deficiency and free fatty acid levels, all of 
which increase oxygen demand.  
 
The hypercoaguable state promotes increased procoagulants such as 
plasminogen activator inhibitor-1, factor VIII and platelet reactivity, as well as 
decreases in endogenous anticoagulants such as protein C and antithrombin 
III (20).  
 
The inflammatory state that is produced releases tumour necrosis factor-
alpha, interleukin (IL)-1, IL-6 and C-reactive protein (21). All of these changes 
can result in increased coronary artery sheer stress and induce coronary 
artery thromboses. A local and systemic inflammatory response is also 
created by blood being exposed to the foreign surfaces of the 
cardiopulmonary bypass circuit (22). Cardiopulmonary bypass will be 
discussed later but this allows surgery to be performed in a motionless, 
bloodless field while providing physiological support through an extracorporeal 
circuit.  
 
Other mechanisms involved in perioperative myocardial ischaemia involve 
technical problems associated with placing coronary bypass grafts and 
valves. These include graft kinking, closure, anastomotic stenosis and spasm 
(23). Inadequate placement or selection of valves with resultant regurgitation 
or failure will also produce myocardial injury (24). 
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Another factor involved in myocardial injury is the length of time for aortic 
cross-clamp and cardiopulmonary bypass times. Aortic cross clamping is 
used to isolate the heart from the systemic circulation so that surgeons can 
operate in a bloodless field during valve and coronary bypass surgery. The 
clamping and declamping of the aorta causes a global ischaemia-reperfusion 
injury. The longer the aortic cross clamp is applied the worse the injury and 
prognosis. Similarly, cardiopulmonary bypass times show a close correlation 
with postoperative mortality and morbidity (25). 
 
1.3.3 Risk factors for perioperative myocardial injury 
As well as the wide variety of mechanisms resulting in perioperative 
myocardial injury it is important that preoperative risk factors be noted as 
these patients are more likely to have postoperative complications and 
increased mortality. Higher risk patients will be more susceptible to 
myocardial injury and so identifying these patients may yield greater benefit 
from cardioprotection strategies. The following preoperative risks are taken 
from the new EuroSCORE II (26) risk model (European System for Cardiac 
Operative Risk Evaluation) which was first announced in 2011 and 
superseded the original EuroSCORE first published in 1999 (27): 
 Age >70 years old 
 Female sex 
 Renal failure 
 Diabetes 
 Peripheral artery disease 
 Emergency or redo surgery 
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 Severe LV dysfunction (LVEF<35%) or cardiogenic shock  
 Preoperative MI 
 Chronic lung disease 
 Poor mobility 
 Surgery on thoracic aorta 
 Surgery other than isolated CABG 
 Pulmonary hypertension 
 NYHA and angina class 
 Active endocarditis 
 
1.4 The need for cardioprotection in cardiac surgery 
1.4.1 Development of cardiopulmonary bypass 
Cardiopulmonary bypass was first developed in the 1950s as it was 
recognised that there was a need for surgery to be performed in a motionless 
and bloodless field. The most credit lies with a surgeon from Boston named 
John Gibbon who made the most pioneering advances during that decade 
and developed cardiopulmonary bypass machinery with many automated and 
safety features (28). Blood is typically drained by gravity from the heart and 
lungs through tubing to a reservoir where it is oxygenated via an oxygenator 
or gas-exchanger and then returned to the cannulated arterial system. The 
bloodless field is created by the application of a cross-clamp to the aorta 
proximal to the arterial cannula but distal to the coronary ostia thereby 
isolating the coronary arteries and cardiac chambers. It was from this that a 
need for myocardial protection was realised due to the risk of myocyte cell 
death from cross clamping the aorta and cardiac bypass itself.  
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1.4.2 Crystalloid cardioplegia  
In the 1960s, cold crystalloid cardioplegic solution was developed to provide 
diastolic electromechanical arrest and hypothermia thereby reducing 
metabolic demands (29). Crystalloid solutions are infused at 4°C antegradely 
down the coronary arteries via the aortic root or coronary ostia, or retrogradely 
from the coronary sinus or both antegradely and retrogradely. Where coronary 
stenoses are severe, antegrade perfusion may not be sufficent. Retrograde 
perfusion is also believed to offer poor perfusion of the right ventricle. For 
these reasons, surgeons may use simultaneous antegrade and retrograde 
infusion.  Potassium is used to induce cardiac arrest at a concentration of 10 
to 20 mmol/L. Crystalloid solutions are differentiated into two types: 
intracellular which contains low sodium, calcium and magnesium 
concentrations, and extracellular which contains these elements at higher 
concentrations. Small amounts of calcium in the cardioplegia solution reduce 
the risk of its intracellular accumulation during ischaemia and reperfusion. 
Due to the risk of calcium paradox, phenomenon complete elimination of 
calcium is not recommended because rapid calcium accumulation during 
reperfusion leads to acute hypercontracture known as ‘stone heart’. The 
addition of magnesium provides a protective antiarrhythmic effect on the 
heart, which also inhibits entry of calcium and decreases uptake of sodium 
into the myocytes during ischaemia. Magnesium is then exchanged for 
calcium during reperfusion. The volume and rate of infused cardioplegic 
solution varies depending on the type of solution and the institution but around 
1L at 50mmHg to 80mmHg for antegrade or 40mmHg for retrograde delivery 
is adequate in most adults to induce cardioplegic arrest with some surgeons 
21 
 
allowing continued infusion for a few minutes afterwards. If the heart resumes 
electrical activity or the cross-clamp time is prolonged then further doses up to 
500 mls may be given at a time (30). 
 
1.4.3 Blood cardioplegia 
Crystalloid cardioplegia has largely been superseded by blood cardioplegia 
because of its oxygen carrying capabilities. Blood cardioplegia involves 
infusion of native oxygenated blood mixed with crystalloid solution in the ratio 
of 4:1, which is passed through a heat exchanger prior to being applied to the 
heart. Standard blood cardioplegia uses cold solution at 8-12°C delivered 
antegradely and retrogradely with reinfusions at 20 minutes and a final ‘warm’ 
or normothermic substrate-enriched infusion prior to aortic unclamping. 
Variations on the traditional cold blood cardioplegia have seen surgeons use 
warm blood cardioplegia induction for patients that have poor LV function and 
acute myocardial infarction. Warm blood cardioplegia is seen to maximise the 
kinetics involved in ‘cell repair’ and the solution is supplemented to replenish 
the compromised hearts with much needed amino acids from the Kreb’s 
cycle. Tepid blood cardioplegia has also evolved as a technique and is felt to 
combine the benefits of warm and cold blood cardioplegia. Intermittent 
antegrade blood cardioplegia has also developed as a method of 
cardioprotection to allow surgery in a bloodless operative field (31), and is the 
preferred technique at our institution and worldwide. 
 
Over the last two decades, there has been considerable debate as to which 
solution and technique for cardioplegia is the best. A meta-analysis of trials 
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found that the only difference was that blood cardioplegia had less low cardiac 
output syndrome and reduced CKMB but no significant difference in endpoints 
of myocardial infarction and death when compared to crystalloid cardioplegia 
(32). The CABG patch trial investigated higher risk surgical patients with poor 
LV function, and found that operative deaths (2% vs. 0.3%), postoperative 
myocardial infarctions (10% vs. 2%) and shock (13% vs. 7%), were 
significantly higher in the cold crystalloid cardioplegia group, although there 
was no difference with early and late survival when compared to the blood 
cardioplegia group (33). In practice, the choice of cardioplegic solution and 
technique ultimately lies with the personal experience of each individual 
surgeon but in the UK antegrade, intermittent cold blood cardioplegia has 
emerged as the choice for surgeons because of its more physiological 
constitution and lower morbidity.  
 
1.4.4 Cross-clamp fibrillation 
An alternative to cardioplegia is cross-clamp fibrillation where the aortic cross-
clamp is applied intermittently after induction of ventricular fibrillation. In the 
UK, around 15% of surgeons prefer this method for CABG surgery (34). 
Reperfusion is allowed after every distal anastomosis in CABG while the 
proximal end of the conduit is anastomosed to the aorta, as it is felt that there 
is no detriment to myocardium with up to 15 minutes of ischaemia. In fact, it is 
proposed that with each subsequent graft there is protection of the 
myocardium afforded by IPC (IPC) (35), a mechanism of cardioprotection, 
which will be discussed later.  Experimental models have added weight to this 
by showing that blockade of reputed IPC cascade factors attenuated any 
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cardioprotective efficacy afforded by intermittently cross-clamped 
(‘preconditioned’) and fibrillated myocardium (36).  
 
1.4.5 Off-pump versus On-pump CABG 
Off-pump CABG was developed to reduce the risk of stroke from 
cardiopulmonary bypass. The main prerequisite of performing surgery on a 
beating and blood-filled heart are that the surgeon has the necessary skills to 
anastomose grafts; however, there are devices available to immobilise the 
relevant areas of the heart requiring suturing. Studies have shown that off-
pump CABG is comparable to on-pump CABG with excellent results (37). 
 
1.4.6 Hypothermia 
Hippocrates a Greek physician first noted the therapeutic effects of 
hypothermia in wounded soldiers packed with snow and ice. William Osler 
another great physician placed his typhoid fever pateints in a cold bath in the 
1890s. Systemic hypothermia during cardiac surgery lowers the metabolic 
rate and oxygen demands of the heart and thereby conferring protection. 
Typically, systemic temperature in cardiac surgeries is reduced to between 
25°C and 34°C. More challenging operations may require a deep hypothermia 
to as low as 15°C. For each decrement in temperature by one degree Celsius, 
there is an approximate 5-7% reduction in metabolism. Hypothermia also 
minimises disruption to cell haemostasis by increasing cell membrane 
stability, which prevents the influx of unwanted ions during ischaemia. Low 
temperatures may also reduce reperfusion injury (RI) by decreasing free 
radical production due to oxidative stress and dampening down the various 
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inflammatory immune responses (38). Reperfusion injury will be discussed in 
more detail later on. 
 
1.4.7 Volatile anaesthetics 
The reader is asked to refer to the sections on ischaemia and reperfusion 
injury and IPC and ischaemic postconditioning prior to reading this section to 
gain an understanding of the mechanisms described.  Volatile anaesthetics 
are gases used to rapidly induce and maintain general anaesthesia. The most 
commonly currently studied volatile anaesthetics are sevoflurane, isoflurane, 
enflurane and halothane.  Animal studies have shown a direct cardioprotective 
role of these agents from ischaemia and reperfusion injury as shown by 
decreased infarct size and more rapid postoperative recovery of contractile 
function. These experimental studies have also helped elucidate some but not 
all of the complex signalling factors involved in anaesthetic preconditioning 
but clinical studies have shown equivocal results in cardiac surgery (39-41).  
 
The most recently studied volatile gases are sevoflurane, isoflurane and 
halothane. Experimental studies have shown that volatile anaesthetic agents 
modulate the K+ adenosine triphosphate (ATP)-sensitive channel or KATP 
channel and the mitochondrial permeability transition pore (mPTP) which 
have both been shown to be cardioprotective mediators in IPC. The opening 
of mitochondrial KATP channels leads to the generation of reactive oxygen 
species (ROS) activating downstream kinases, resulting in cardioprotection 
(42). Another pathway involved in cardioprotection and volatile anaesthetic 
agents is Phosphatidylinositol-3-Kinase and Protein Kinase B (Akt/PI3k) 
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pathway which is a key intracellular signal pathway involved in apoptosis. 
Evaluation of the Akt and phosphorylated-Akt (active Akt) expression during 
ischaemia and reperfusion revealed higher expression in ischaemia-
reperfusion and volatile anaesthetic (isoflurane) pre-treated groups with 
administration of PI3K inhibitors leading to inhibition of phosphorylated Akt 
and repeated inhibitor administration abolishing the cardioprotective effects of 
anaesthetic pre-treatment (43). Similarly the extracellular-signal kinases 
(ERK) pathway have been linked to myocardial protection elicited by volatile 
anaesthetics but this is dose dependent with an experimental study showing 
that a second dose of desflurane diminished cardioprotection and that 
although the ERK1/2 are downstream effectors of PKC their activation (i.e. 
phosphorylation) is independent (44).  
 
It is also well recognised that reperfusion injury is a result of the accumulation 
of Ca2+ that leads to activation of nuclear factor-κB (NF-κB), which causes 
release of inflammatory mediators. Experimental studies have shown that rats 
pre-treated with sevoflurane had reduced infarct size and that by inhibiting 
NF-κB led to even greater protection from ischaemia than sevoflurane 
administration alone (45). 
 
In the clinical setting for volatile anaesthetics, there have been conflicting 
results with trials only showing some protection with respect to cardiac 
function and troponin release but no evidence of reduced risk of myocardial 
infarction or cardiovascular mortality (46-48).  Despite this, the 
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recommendations from the ACC/AHA guidelines state that patients at risk for 
myocardial infarction during non-cardiac surgery would benefit from 
pretreatment with gas anesthesia, if hemodynamically stable (49). Future 
investigations need to evaluate the most optimal anaesthetic agent, 
concentration and administration protocol for the best cardioprotective effects 
as studies have noted a difference in benefit based upon pretreatment (50). 
This probably best explains why experimental models have not translated 
their results in clinical studies. 
 
1.4.8 Intravenous glyceryl trinitrate and IPC 
Intravenous glyceryl trinitrate (GTN) is often given during cardiac surgery after 
anaesthetic induction as a means to control blood pressure. Its benefits are 
that it has a rapid onset of action, and a short-half life so blood pressure can 
be controlled tightly through careful titration of this drug. GTN is also given on 
the assumption that it results in coronary vasodilatation pre-operatively and 
may maintain graft patency post-operatively. GTN may play a role in reducing 
IR injury. It is known that short-term exposure to GTN has protective 
properties similar to IPC (51). Damage and dysfunction to the vascular 
endothelium can influence outcomes after IR injury but nitrates may protect 
against this (52). The exact mechanisms remain poorly defined, but it is 
postulated that nitrates and other nitric oxide donors trigger signalling 
cascades and induction of protective genes and pathways mentioned earlier 
(53). Bolli et al. describe a mechanism for late preconditioning and suggested 
that NO and secondary species activate PKCε either directly or via reactive by 
products. PKCε leads to further signalling through various kinases and 
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transcription factor NF-κB and other unknown components resulting in 
increased inducible nitric oxide synthase (iNOS) activity, which is responsible 
for protection (53). Others have proposed that instantaneous mitochondrial 
ROS release induced by GTN amongst other mediators, leads to increased 
expression of protective molecules and enzymes such as superoxide 
dismutase, haem-oxygenase and calcitonin gene related peptide (53, 54, 55). 
A human in vivo study by Gori et al. in 2010 showed that in subjects that 
received transdermal GTN for 2 hours there was a prevention of the 
endothelial dysfunction caused by IR injury in the arm. However, after 1 week 
of chronic administration of GTN the protective effect seen was lost.  In the 
chronic administration group, the endothelial responses were blunted before 
IR and subsequent IR did not cause further dysfunction. The same 
investigators also used a separate experimental model to show that in 
isolated human endothelial cells, short-term incubation with GTN caused up-
regulation of haem oxygenase, an effect that was lost after prolonged GTN 
administration.  They therefore proposed that a short duration of GTN therapy 
is able to protect the endothelium from IR injury endothelial dysfunction but 
that this protection was lost upon prolonged administration possibly through 
an oxidative mechanism. Further to this, animal and human studies have 
documented the non-haemodynamic cardioprotective effects of GTN resulting 
in a reduced myocardial sensitivity to IR injury (51, 55, 56). 
 
1.5 Cardiac Troponins 
1.5.1 Description 
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Cardiac troponin (cTn) is a complex of three regulatory troponins (troponins C, 
T and I) which produce myocardial contraction through control of the calcium-
mediated interaction between actin and myosin. The troponin regulatory 
proteins are integral to muscle contraction in skeletal and cardiac muscle but 
not in smooth muscle. During myocardial cell death these cardiac cTn 
proteins are released into the blood. Since the early nineties highly sensitive 
and cardiospecific immunoassays for cTn T and cTn I have come into regular 
clinical use. These superseded the use of the cardiac biomarker creatinine 
kinase MB (CK-MB) and have become the cornerstone of assessment in 
acute coronary syndromes (57, 58). cTn C is not useful for detecting cardiac 
muscle injury as its isoform is shared by skeletal muscle. Raised troponin 
levels are therefore indicative of myocardial necrosis but they do not 
determine the mechanism for their elevation. Troponins are internationally 
recommended as the cardiac biomarker of choice in the diagnosis of acute 
coronary syndromes and myocardial infarction as well as acting as an 
adverse prognostic marker. The 2012 Third universal definition defined 
myocardial infarction after CABG as requiring a troponin rise >10-times 99% 
upper reference limit (URL) from a normal pre-operative level (59). In fact, 
various studies have in fact shown that the true inflection point for cTn 
elevations to be deemed prognostic is actually higher. Indeed cTn elevations 
should always be interpreted with caution as many factors contribute to 
elevated cTn readings in post-operative patients on intensive care units, other 
than perioperative myocardial injury. For example, even the type of cardiac 
surgery performed has a bearing with valve only surgery releasing less 
troponin than CABG (60). Post-operative complications can also increase 
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troponin such as pulmonary embolus, acute renal failure, hypotension, sepsis, 
pericarditis and heart failure (61). With this in mind, studies have shown that 
raised troponin is prognostic in postoperative cardiac surgery with greater 
elevations associated with delayed recovery, increased stay on intensive care 
as well as short and longer-term mortality. 
 
1.6 Myocardial Ischaemia-reperfusion injury  
1.6.1 Ischaemia 
Myocardial ischaemia develops when there is inadequate supply of oxygen to 
an area of myocardium usually through diminished blood flow. This results in 
a cascade of metabolic and biochemical events causing ionic changes within 
cells. Within the cell low oxygen levels result in ATP depletion which cause 
cell swelling through the accumulation of sodium (Na+) and water and 
expulsion of potassium (K+). Metabolism switches to anaerobic respiration 
causing the accumulation of toxic lactate, which lowers the pH to below 7.0 
resulting in acidosis. This causes activation of the sodium-hydrogen (Na+-H+) 
exchanger removing H+ in place of Na+, which becomes intracellularly 
overloaded (62). Further Na+ overloading occurs within the cell through the 
resultant decline in 3Na+-2K+ ATPase function through depleted ATP. Due to 
rising intracellular Na+ levels the 2Na+-Ca2+ ion exchanger that normally 
imports Na+ into cells works in reverse resulting in intracellular Ca2+ 
overloading. Ca2+ overload results in electrical instability, mitochondrial 
dysfunction and mechanical dysfunction with further usurping of ATP and 
resultant cell death. 
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1.6.2 Reperfusion injury 
Initially myocardial cell death was felt to be due to ischaemia only but 
increasingly, reperfusion has been shown to play a role, although with some 
controversy (63). Reperfusion was seen to replenish blood supply and 
therefore prevent further ischaemic damage and so cells that died during the 
reperfusion phase were considered as already irreversibly injured. The best 
way to prevent ischaemic cell death was to replenish or reperfuse the 
myocardium as soon after the onset of ischaemia as possible. Reperfusion 
strategies such as primary percutaneous coronary intervention (PPCI) have 
always focused on prompt intervention and resulted in the well-known adage 
that time is myocardium (64). Despite this evidence emerged that reperfusion 
could damage myocardium and this was termed ‘lethal reperfusion injury’ and 
defined as being a period after ischaemia where an intervention could reduce 
the reperfusion injury (65). Despite these strategies to reduce reperfusion 
injury by varying reperfusion, conditions have proved successful in 
experimental models but have eluded researchers in clinical trials (66).  
 
Two reversible forms of myocardial reperfusion injury exist which are 
malignant ventricular arrhythmia and myocardial stunning. Myocardial 
arrhythmia during reperfusion is a well-recognised phenomenon which is 
either self-terminating or can be reversed by various therapeutic measures or 
indeed can result in death if there is prolonged haemodynamic compromise. 
The observation that ventricular arrhythmia occurred more frequently during 
reperfusion than during coronary artery occlusion itself was first made in 1960 
(67). ‘Myocardial stunning’ as a term, was first coined in 1982, and is defined 
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as a delay in the recovery of function of myocardium after reperfusion despite 
no myocardial damage and the restoration of blood flow (69). Various 
mechanisms have been postulated in the pathogenesis of stunning but 
current thinking lends itself to calcium overload and oxygen-derived free 
radicals (69, 70). 
 
The third form of reperfusion injury is irreversible and termed microvascular 
obstruction (MVO). This is an inadequate reperfusion of the ischaemic 
myocardial territory despite removal of coronary artery obstruction and occurs 
at the level of the microvasculature – structural changes at this level impede 
flow. During PCI, this phenomenon is seen as sluggish blood flow at the time 
of coronary angiography down a visually normal coronary artery and is termed 
as no-reflow (71). The major contributor to MVO is the massive neutrophil 
activation and infiltration of platelets that adhere to capillary endothelium as 
well as forming aggregates, which cause mechanical obstruction to blood flow 
(72).  Activated neutrophils also release oxygen free radicals, inflammatory 
mediators and proteolytic enzymes that can cause cellular oedema and 
further endothelial damage. Swollen myocytes caused by the oedema and 
extravasated red blood cells also extrinsically compress the microvasculature 
contributing to further MVO. Microemboli from artherosclerotic plaque are also 
sent downstream causing further mechanical obstruction and vasoconstriction 
of the coronary microcirculation caused by release of vasoconstrictors from 
damaged endothelial cells, neutrophils and platelets play a role (73). The 
fourth recognised form of reperfusion injury is termed ‘lethal reperfusion injury’ 
and refers to death of cardiac myocytes that were considered to have 
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reversible injury at the end of ischaemia. The proposed contributors to 
reperfusion injury are oxidative stress; restoration of physiological pH from the 
acidosis caused by ischaemia and mitochondrial transitional pore (mPTP) 
opening, Ca2+ overload and associated hypercontracture (74).   
 
1.6.3 The mitochondrial permeability transition pore 
The mPTP is a nonselective, voltage-dependent channel within the inner 
mitochondrial membrane, that is closed under normal physiological 
conditions, and is impermeable to solutes. Research over the last two 
decades has shown that during ischaemia, the pore remains closed probably 
due to acidic and toxic lactate-induced conditions (75) created during 
ischaemia but during the first few minutes of reperfusion the pore opens 
resulting in inner mitochondrial membrane permeability, leading to matrix 
swelling and subsequent cell death. Oxidative stress and calcium influx during 
reperfusion are seen to have an influence on mPTP opening directly. As 
mentioned above during ischaemia oxidative stress occurs resulting in ionic 
changes culminating in intracellular Ca2+ overloading. Acidosis prevents 
mPTP opening during ischaemia, however, during reperfusion there is a burst 
of ROS formation, a return to physiological pH with washout of lactate, which 
all restores mPTP opening. There is also uncoupling of mitochondrial 
oxidative phosphorylation and further aggravation of calcium influx further 
propagating the opening of the mPTP leading to myocyte death (74, 76). The 
mPTP has therefore led to renewed interest as a target for cardioprotection 
during reperfusion with inhibition of its opening in experimental models 
yielding promising results but this is yet to be translated into clinical trials. 
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Cyclosporin A is known to be a direct inhibitor of mPTP and Piot et al. showed 
that in 58 patients undergoing PCI there was a decrease in infarct mass after 
5 days quantitated by cardiac MRI when cyclosporine A was given (46g vs 
36g) but no significant difference in cardiac enzymes (77). Subsequent to this 
the Cyclosporine before PCI in Patients with Acute Myocardial Infarction 
(CIRCUS) trial published in 2015 failed to show better clinical outcomes in 
patients with anterior ST-elevation myocardial infarctions that received an 
intravenous bolus injection of cyclosporine when compared to those patients 
that did not (78). This international, multicenter, randomized, double-blinded, 
placebo-controlled trial recruited 970 patients. The primary outcome of the 
trial, a composite end-point including all-cause mortality, worsening heart 
failure during the admission, rehospitilisation for heart failure and adverse 
ventricular remodeling at 1 year occurred in 59% of the 395 patients 
randomised to cyclosporine and 58.1% of the 396 patients randomised to 
placebo. This was not statistically significant and yielded neutral results. 
However, the results of the trial were questioned in an editorial by Hausenloy 
and Yellon, as the findings for the end point of left ventricular remodeling were 
not robust and also a completely different preparation for Cyclosprin was used 
compared to that which had been used in previous experimental studies and 
yielded positive data (79). Therefore, IPC may possibly exert its 
cardioprotective effects through the mPTP, resulting in inhibition of its opening 
during reperfusion. IPC refers to short burst of sublethal ischaemia prior to the 
actual ischaemic insult, which may protect against reperfusion injury and will 
be discussed in the next section.  
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1.7 IPC 
1.7.1 Background and conception 
Initial studies into therapeutic interventions at the time of coronary artery 
occlusion lacked control for baseline variables and had poor models for 
quantification of infarct size (80). The story of IPC (IPC) therefore actually 
begins in 1986 with Murry et al. who presented this cardioprotective 
phenomenon using the canine model (81). They used anaesthetised dogs and 
found that by instigating four cycles of 5 minutes of ischaemia with intervening 
5 minute periods of reperfusion there was a significant decrease in infarct size 
in the intervention arm compared to controls after the circumflex coronary 
artery was ligated for 40 minutes. Since then research has focused on 
elucidating some of the signal transduction pathways involved in this 
phenomenon. Yellon and Downey (82) provide a useful division of labours 
here by dividing, signalling into triggers which occur after the preconditioned 
stimulus and before a memory element which keeps the heart 
‘preconditioned’. Signalling that occurs after the memory element involves 
mediators and includes the end-effectors, which exert their protective effect 
on the myocardium during the index ischaemia or reperfusion.   
 
1.7.2 Two windows of protection 
Preconditioning affords itself two distinct time zones for protection and 
although the triggers are shared, there is a difference in the potential 
mediators. The first zone or window for protection lasts up to 2 to 3 hours after 
the preconditioning stimulus and this is referred to as the acute or classical 
preconditioning window (81).  There then lies a second window of 
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preconditioning (SWOP) and this begins 12 hours after the stimulus and can 
last up to 72 hours (83). The SWOP allows for the possible mediators of 
cardioprotection to be because of protein biosynthesis, post-translational 
protein modification (manipulation of polypeptide structure prior to it becoming 
its mature protein product) or movement of protein between compartments 
(80). 
 
1.7.3 Triggers  
Proposed triggers of IPC include adenosine, bradykinin, prostaglandins, nitric 
oxide, Ca2+, opioids and noradrenaline (84). Receptors for these triggers act 
in tandem to precondition the heart and result in activation of Gi protein. 
Observation that these receptors work in parallel comes by virtue of the fact 
that blockade of a single receptor in experimental models requires an 
increase to the IPC stimulus to afford protection (85). Free radicals may also 
act as triggers for preconditioning (86) by activating kinases with their origin 
being the result of xanthine oxidase on purine metabolism or perhaps more 
complex mechanisms (80). Animal models also suggest another trigger, which 
acts without receptor, may also be Ca2+ which itself may cause a 
preconditioned state or be involved in IPC (87).  Nitric oxide (NO) may have a 
novel dual role in IPC as trigger or mediator but notably evidence for its role is 
considered to be in late preconditioning rather than early (88). There are even 
reports that suggest its role may be simply to lower the threshold for 
preconditioning rather than be involved in signalling (89). 
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1.7.4 Mediators 
The Protein Kinase C (PKC) family of enzymes are involved a variety of 
physiological processes and their role in cardioprotection has been 
investigated with vigour. PKC is split into three groups dependent on their 
responsiveness to diacylglycerol (DAG) or Ca2+ for enzyme activity. The α, 
βI, βII, and γ isozymes of PKC are both DAG- and Ca2+-dependent. The ε, δ, 
θ, and η isoenzymes are only DAG-dependent and do not require Ca2+ for 
activity. Isoenzymes, which are neither DAG- nor Ca2+-dependent and require 
lipid-derived molecules for activity are referred to as the atypical PKCs; ζ and 
λ (90). Evaluation of the individual isoforms roles in cardioprotection has 
involved isozyme-specific modulators as well as transgenic and knockout 
mice of specific PKC isoenzymes. PKC isoenzymes each anchor to unique 
docking sites called receptor for activated C-Kinase (RACK), which results in 
isozyme activation and therefore phosphorylation of any local substrate (91). 
Various studies have shown that PKCε has a major role in IPC resulting in 
reduced cell death (92-94). Conversely, the isoenzyme PKCδ has been found 
to cause cell death by promoting damage from ischaemia and its inhibition is 
cardioprotective (95). ROS, which is harmful to cardiac myocytes, has been 
identified as an activator of PKCδ (96).Unfortunately despite these findings 
the signalling mechanisms that directly link PKC to preconditioning have not 
been completely characterised. Postulated mechanisms include the 
generation of free radicals, changes in the levels of pro- and anti-apoptopic 
proteins of the Bcl-2 family and activation of the mitochondrial ATP-sensitive 
potassium channel (mitoKATP) 
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PKCε has been shown to directly interact in the inner mitochondrial 
membrane and is required for the opening of mKATP (97). mKATP channels 
have been shown to potentiate cardioprotection through use of channel-
activating drugs or inhibitors which reverse the protective effects seen. Initially 
studies had shown that exogenous cyclic GMP (cGMP) and protein kinase G 
(PKG) activates mKATP and was reversed by inhibitors of PKC (98) which 
strongly lends itself to PKG transmitting its cardioprotective signal to through a 
PKC pathway. Current thinking for signal transduction in IPC resulting in 
mKATP is through the PI3K–Akt–eNOS–cGMP–PKG pathway (99). mKATP then 
goes on to generate ROS which activate survival kinases. The KATP channel is 
normally inhibited by ATP and is modulated by pH, NO, fatty acids, G proteins 
and ligands such as adenosine (100). They have been shown to be important 
mediators in cardioprotection and downstream to adenosine receptor 
activation as this can be blocked by glibenclamide, which is a K+channel 
blocker (100). PKC has been shown to activate sarcolemmal KATP channels in 
experimental models (101). 
 
1.7.5 Reperfusion injury salvage kinase (RISK) pathway  
Other potential mediators of IPC are conceptualised into groups of pro-
survival anti-apoptotic protein kinases termed the RISK pathway (102). The 
first members of this cardioprotective unit were PI3-kinase/Akt and the 
p42/p44 mitogen-activated kinase Erk1/2 which conferred cardioprotection 
during reperfusion. Activation of both pathways is through G-protein coupled 
receptors (G-PCR) or growth hormones and descends onto downstream 
kinases such as p70S6 kinase and glycogen synthase kinase 3 β (GSK3-β). 
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The RISK pathway also includes other reperfusion salvage kinases mentioned 
above: PKC and PKG. In conflict to this the RISK pathway is the already 
mentioned PKCδ and rho-kinase which is deleterious to myocytes and 
counteracts RISK pathway protection (103). Mitogen activated kinases 
(MAPK) p38 and c-Jun N-terminal (JNK) controversially exhibit beneficial and 
harmful effects (104). An alternative to the RISK pathway is the surviving 
activating factor enhancement (SAFE) pathway involving tumour necrosis 
factor α (TNF–α), PKG, sphingosine and the Janus Kinase/Signal Transducer 
and activator of transcription JAK/STAT3 system (105, 106). Janus 
Kinase/Signal Transducer and activator of transcription JAK/STAT3 has 
mainly been implicated in delayed preconditioning through its activation of 
nuclear transcription factors.  
 
1.7.6 End-effectors 
The survival kinase pathways appear to converge on the mitochondrion and 
specifically the mPTP which is described above. Its role here as an end-
effector is realised by its inhibition of opening to limit infarct size in ischaemic 
preconditioning and postconditioning but unfortunately the exact mechanism 
underlying this phenomenon remains elusive.  
 
1.8 Ischaemic postconditioning 
1.8.1 Conception 
Ischaemic postconditioning (IPost) is a method for protecting the myocardium 
by interrupting early reperfusion with short-lived episode of ischaemia, and it 
may have partially been borne from observation that slow reperfusion was 
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beneficial over rapid reperfusion (107). The actual technique involves several 
brief periods of ischaemia during reperfusion such that reperfusion is halted 
periodically and then allowed to resume. In 2003, Zhao et al. (108) 
demonstrated the concept by applying a protocol of IPC in reperfusion (i.e. 
postconditioning). Their protocol involved LAD ischaemia in anaesthetised 
open-chest dogs with the preconditioned arm involving 5 minutes occlusion 
followed by 10 minutes reperfusion and then 60 minutes ischaemia. In the 
postconditioning arm, there were three cycles of 30-second reperfusion and 
30-second reocclusion. They showed that preconditioning and 
postconditioning similarly and significantly reduced infarct size and tissue 
oedema while preserving endothelial function when compared to controls.  
 
1.8.2 Mechanistic insight 
Initially it was believed that IPost was simply exerting its effect mechanically 
by causing a gradual low-pressure reperfusion thereby limiting the negative 
effects of reperfusion injury such as oxidative stress, calcium accumulation, 
myocardial oedema and inflammation (109). Indeed some felt that IPost and 
IPC had different pathways as the interventions lay at either end of ischaemia 
(108). However, subsequent studies have found that many of the signalling 
pathways recruited in IPost are similar to those seen in IPC. In fact, the first 
data that prosurvival kinases seen in IPC were also involved in IPost came 
from the Yellon group in 2004 who showed the involvement of PI3K/Akt 
pathway (110). Other prosurvival kinases shown to be involved in a common 
pathway include ERk1/2 thereby implicating the RISK pathway (111) Now 
after much research it is accepted that preconditioning and postconditioning 
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activate the same key pathways beginning with upstream GPCRs including 
adenosine, bradykinin, opioid and sphingosine-1-phosphate (SIP) receptors. 
As well as this, experimental studies have shown that IPost activates the 
JAK/STAT3 pathway, which is known to also be involved in the SWOP (112, 
113). Another common mediator not yet mentioned is Hydrogen sulphide 
(H2S) which activates RISK (114) and is seen in IPC and IPost. In the end, all 
of these signalling pathways appear to converge on the mPTP as in IPC.   
 
 
1.8.3 Evidence 
Human studies have had conflicting results with the first landmark study by 
Staat et al. investigating postconditioning in patients that underwent direct 
stenting during PCI for acute myocardial infarction with an intervention group 
having 4 cycles of 1-minute angioplasty balloon inflation and 1-minute 
deflation before full reperfusion. Results showed that there was a reduction in 
CK release quantified by area-under-the-curve at 72 hours. There was also 
significant improvement in blush grade at angiography, which is a marker of 
reperfusion (115). Further studies showed IPost infarct-limiting capabilities by 
a variety of assessment modalities, which included troponin release and left 
ventriculography with follow up at 1 year (116) and cardiac MRI (117). In stark 
contrast to this, there have been negative clinical studies, which also used the 
accepted postconditioning algorithm of 4-minute cycles of ischaemia and 
reperfusion within actual reperfusion. Friexa et al. looked at 79 patients 
undergoing PCI for a first STEMI, found that there was no difference in infarct 
size as assessed by MRI at 1 week, and 6 months and in fact 
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postconditioning was associated with lower myocardial salvage and salvage 
index along with an enhancement of troponin release (118). Although results 
are conflicting there is still optimism regarding IPost being a genuine 
phenomenon and failure of clinical studies has been put down to confounding 
factors that may attenuate its protection in studies. For example, age is known 
to reduce cardioprotective signalling as seen in mice but not rats (119). 
Various co-morbidities are known to interfere with cardioprotection and IPost 
such as hypercholesterolaemia, diabetes, obesity and hypertension. Drugs 
may also play a role and affect IPost by recruiting cardioprotection in control 
groups. These include adenosine, GTN, B-blockers, angiotensin converting 
enzyme (ACE) inhibitors and statins that are all given around the time of PCI 
(120). However, our current understanding is insufficient to quantify the extent 
of the roles played by these confounders. 
 
A few conclusions can be drawn from the above experimental and clinical 
research bearing in mind the potential reasons why a translation to bedside 
results has not been seen. Firstly, the extent of protection in IPost is 
dependent on the duration of ischaemia and postconditioning protocol used 
with species and inter-individual variations being clearly apparent. Secondly, 
there is a need for the actual clinical benefit of IPost to be seen with large 
multicentre studies showing outcome data to build on the smaller human 
studies that have shown non-prognostic benefit through cardiac enzyme 
release and infarct size reduction using imaging modalities. 
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1.9 Remote IPC (RIPC) 
1.9.1 Conception 
IPC has had limited clinical application because of the inability to predict the 
onset of ischaemia in myocardial infarction, which has restricted its application 
to elective cardiac surgery. IPost has been investigated in small trials at the 
time of PCI but conflicting results, concerns over interrupting reperfusion, 
lengthening procedural time and the issues surrounding funding due to limited 
incentive for industry, have also meant that large multicentre trials have not 
been realised (121). From this, the concept of RIPC has evolved in the last 
decade as a mechanism for cardioprotection from IR injury through the 
preconditioning stimulus being performed at sites remote to the heart. As a 
concept, its origins lie in a canine model experiment by Przyklenk et al. in 
1993 (122). Anaesthetised dogs underwent four 5-minute cycles of ischaemia 
and reperfusion in the circumflex artery territory which resulted in 
cardioprotection in the subsequently infarcted LAD territory. This suggested 
that IPC performed in one vascular bed afforded protection in another 
coronary artery territory. It was postulated that this was mediated by factors 
created, activated or transported through the heart. Since then inter-organ 
protection has been demonstrated by a preconditioning stimulus being applied 
to small bowel (123) or kidney (124) and this resulting in decreased infarct 
size in the heart. After this Birnbaum et al. (125) showed that by reducing 
femoral artery blood flow and pacing the gastrocnemius muscle followed by 
30 minutes of coronary artery flow occlusion and 4 hours of reperfusion 
resulted in significant reduction in infarct size when compared to controls. 
From this a simple, safe, cheap and easily instituted stimulus to investigate 
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cardioprotection was born. The preconditioning stimulus could be applied to 
the arm or leg by performing cycles of ischaemia and then reperfusion using 
blood pressure cuffs inflated to suprasystolic blood pressure and then 
deflated. This resulted in experimental RIPC studies in humans showing 
cardioprotection and laid the platform for a large number of clinical trials.  
 
1.9.2 Mechanistic insight – Humoral pathway 
RIPC appears to confer two distinct phases of protection like IPC. The first 
phase vanishes within 4 hours whereas the second prolonged phase lasts for 
at least 48 hours (126, 127). There is also a growing body of evidence that 
reduction in infarct size can be induced by applying the ischaemic stimulus 
after the index ischaemia during reperfusion and this is termed Remote 
ischaemic postconditioning (RIPost). Signalling is believed to be through both 
a humoral and neural pathway. The potential humoral factor is blood-borne 
and represents a mode of communication between the site of the protective 
stimulus and the target tissue or organ. Evidence for a humoral factor in 
mediating systemic spread is supported by two studies in 1999 by Dickson et 
al. that showed when the transfusion of serum from rabbits that had 
undergone an IPC protocol to rabbits which had not resulted in 
cardioprotection (128, 129).  Konstantinov et al. showed that a pig, which had 
undergone RIPC of a limb and then received a denervated donor heart 
exhibited cardioprotection strongly suggesting a humoral role rather than a 
neural role (130). The humoral factor is as yet unidentified but appears to be a 
small hydrophobic molecule which is heat labile, dialysable, less than 15 kDa 
and blocked by pre-treatment with the opioid antagonist naloxone (131, 132). 
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Studies have also looked at whether endogenous mediators such as 
bradykinin, adenosine, opioids, endocannabinoids and CGRP are released 
from the remote organ during the preconditioning ischaemia and are carried 
via the blood to the heart where they activate intracellular signalling pathways 
or they may activate afferent neural pathways within the remote 
preconditioned organ (133).  
 
1.9.3 Mechanistic insight – Neural pathway 
Neurogenic mechanisms have been explored by virtue of autonomic ganglion 
blockade. Hexamethonium abrogated RIPC protection of infracted rat hearts 
achieved by mesenteric artery occlusion had no effect on IPC of the heart 
(134). In 2005, MaCallister’s group also showed that in humans the autonomic 
ganglion blocker trimethaphan inhibited RIPC. They measured endothelial IR 
injury following 20 minutes arm ischaemia by flow mediated dilation and 
protection conferred by RIPC of three 5 minutes IR cycles in the contralateral 
arm was attenuated by trimethaphan (127).  
 
1.9.4 Mechanistic insight – Systemic response 
There is also some evidence of a systemic response to RIPC involving cross 
talk with immune cells (135) and suppression of an inflammatory response 
with Konstantinov’s group suggesting that RIPC modifies myocardial gene 
expression through the upregulation of cardioprotective genes and 
suppression of genes involved in the pathogenesis of IR injury (136). They 
also showed that brief forearm RIPC suppressed pro-inflammatory genes in 
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circulating leucocytes expressing cytokine synthesis, leucocyte chemotaxis, 
adhesion, migration and apoptosis (137).  
 
1.9.5 Signalling  
Once the signal that RIPC has taken place and reached the myocardium then 
the intracellular transduction mechanisms are activated which are similar to 
those seen in IPC and IPost. As mentioned previously these include the G-
protein cell surface coupled receptors such as adenosine and opioids. Again, 
the prosurvival kinases of the RISK pathway are implicated as well as other 
signalling components such as NO, heat shock proteins, iNOS and the mKATP 
channel. Ultimately, it is felt that this all converges on the mPTP with the 
signalling cascade causing its opening at reperfusion and therefore resulting 
in cardioprotection. 
 
Unfortunately despite much compelling data in experimental models and 
some promising results in initial studies there is a gap in our knowledge of the 
fundamental science involved in RIPC protection. Firstly, the optimal algorithm 
involved in creating the ischaemia reperfusion stimulus has yet to be 
elucidated with the number and length of cycles still needing to be fully 
established. Another issue with studies in RIPC is there is no consensus on 
whether the magnitude of cardioprotection is greater with arm ischaemia 
rather than leg ischaemia and whether two simultaneous limb sites are better 
than one. Despite this RIPC has the potential to provide a prognostic yet cost 
effective means to improve outcomes in patients at risk of myocardial IR injury 
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and what is needed from here is large multicentre clinical trials to provide 
proof of concept (138).  
 
 
1.10 Studies of RIPC 
1.10.1 RIPC in cardiac surgery 
The first clinical trial in this area was in 2000 and this was a small study of 
eight patients who were randomised to receive RIPC or be controls. The 
protocol involved two 3-minute cycles of forearm blood pressure cuff 
ischaemia inflated to 300mmHg with intervening 2 minutes reperfusion (139). 
This study demonstrated an increase in lactate dehydrogenase (LDH) in the 
preconditioned group suggestive of the myocardial cells maintaining their 
ability for anaerobic metabolism. Creatinine phosphokinase (CPK-MB) values 
were not different between the two groups but this was attributed to the fact 
that the study was grossly underpowered and CPK-MB levels were only taken 
5 minutes after unclamping the aorta. It was also felt that the RIPC protocol 
was inadequate (138). Following this in 2006 Cheung et al. were the first to 
show a potential benefit of RIPC in the setting of 37 paediatric surgery 
patients having corrective congenital cardiac surgery. Four cycles of 5 
minutes lower limb ischaemia prior to surgery were effective in reducing cTn 
levels, postoperative inotropic requirements and airway resistance at 6 hours 
(140). Another study involving cardiac congenital heart disease patients 
having ventricular septal defect repair demonstrated that preconditioning 
resulted in an improvement in lung compliance and a decrease in LDH, CK 
and cTn and the cytokines IL-6, IL-8, IL-10, and TNF- (141).  
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Subsequent to this Hausenloy et al. in 2007 showed in 57 adult patients 
undergoing CABG surgery that serum troponin T levels were significantly 
reduced at 6, 12, 24 and 48 hours when undergoing 3 cycles of upper arm 
ischaemia lasting 5 minutes by cuff inflation to 200mmHg with subsequent 5 
minutes reperfusion. Total area-under-the-curve for troponin at 72 hours was 
reduced by 43% (142). Patients in this study underwent both cross-clamp 
fibrillation and cardioplegia. The cardioprotective effects of RIPC in CABG 
patients was also demonstrated in the presence of cold blood cardioplegia 
(143). Similar results were found in a study published in 2010 by Thielmann et 
al., which looked at 53 non-diabetics with triple vessel disease who underwent 
CABG with crystalloid cardioplegia (144). They found a 45% reduction in cTn I 
72 hour area-under-the-curve after left upper arm RIPC with 3 cycles of 5 
minute transient cuff inflation to 200mmHg with 5 minute reperfusion.  A meta-
analysis published in 2012 looked at nine studies totalling 704 patients that 
had undergone CABG due to conflicting data and small sample size. They 
found that RIPC reduced cTn release, even when excluding trials that used 
the infrequently practiced method of cross-clamp fibrillation, off-pump CABG, 
and studies using isoflurane as an anaesthetic agent (which is believed to 
precondition myocardium itself). Postoperative creatinine and hospital stay 
were not influenced (145). 
 
In contrast to the above results, a slightly larger study of 162 patients by 
Rahman et al. was published in 2010, which did not show reduced troponin 
area-under-the-curve at 72 hours (146). They also found that there was no 
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correlation with blood haemodynamics, renal dysfunction, lung injury or total 
hospital intensive care unit stay (ICU) stay. This was a single centre, 
prospective randomised placebo-controlled trial with 3 cycles of 5 minutes 
upper arm ischaemia and 5 minutes reperfusion. This study was praised 
because of its use of a scrupulous technique to remove inadvertent bias by 
blinding the surgeon, anaesthetist and investigators to the group allocation by 
using a dummy arm placed under the surgical drapes next to the left arm, 
which had a cuff placed on it. A cuff was also sited on the patient’s left arm 
and the cuff to be inflated was covertly operated through a switch mechanism. 
Isoflurane was also specifically avoided in this study. Limitations of this study 
and potential confounders were that there was a higher use of B-blockers pre-
operatively. Bypass and cross-clamp times were also higher when compared 
to other studies.  Non-elective patients were also included that may have had 
angina in the preceding 30 days or an acute coronary syndrome. It is possible 
that subtle differences in preconditioning may occur in these groups. 
 
This was followed up with a study published in 2013 enrolling 329 patients 
over 4 years undergoing elective CABG with cold crystalloid cardioplegia and 
cardiopulmonary bypass in Germany also used the same RIPC protocol of 
three 5-minute cycles of ischaemia and reperfusion in the upper arm (147). 
They showed that troponin area-under-the-curve was lower at 72 hours and in 
the preconditioned patients. The secondary end points comprised all-cause 
mortality, major adverse cardiac and cerebrovascular events (MACCE) and 
repeat revascularisation at 30 days, 1 year and completion of follow-up 
ranging from 1 to just over 4 years with a mean of 1.54 years. They found that 
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there was also lower all-cause and cardiac mortality as well as MACCE in the 
RIPC group. They also found that RIPC reduced sepsis, stroke and non-
cardiac deaths adding weight to the theory that RIPC has a multitude of 
systemic benefits.  
 
In contrast to this a study in 2014 published by Hong et al. did not show 
improvement in clinical outcome in 1280 patients undergoing cardiac surgery 
however the patients were randomised into a control group or a group that 
received RIPC and Remote ischaemic postconditioning (RIPost) (148). In the 
intervention arm, four cycles of 5-minute ischaemia and 5 minute reperfusion 
were administered twice to the upper limb before cardiopulmonary bypass or 
coronary anastomoses for RIPC and after cardiopulmonary bypass or 
coronary anastomoses for RIPost. This group did not show a reduction in the 
primary endpoint, a composite of major adverse outcomes, including death, 
myocardial infarction, arrhythmia, stroke, coma, renal injury or multiorgan 
failure. Lengths of intensive care unit and duration of hospital stay showed no 
difference. Notably there was a significantly increased composite endpoint in 
the off-pump subgroup. The strengths of this study were that randomisation 
involved a large population recruited over a short period from June 2009 to 
November 2010. Limitations included patients undergoing different cardiac 
surgeries encompassing CABG, valve surgery, combined CABG and valve 
surgery, ascending or transverse aortic surgery and congenital heart defect 
repair were included so that the heterogeneity probably introduced bias. As 
well as this, the higher risk patients who may have been more likely to benefit 
from preconditioning such as those with poor left ventricular function were 
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excluded. Another factor may have been the addition of RIPost to the RIPC 
protocol. Furthermore, every patient received propofol in their anaesthetic 
regimen, which has been shown to interfere with the activation of the signal 
transducer and activation of STAT5 pathway and hence abrogate the 
cardioprotection of RIPC (149). 
 
Therefore, although several small trials have shown benefit in RIPC with 
improvement in cardiac enzymes and sometimes outcome data there is also 
conflicting data suggesting no benefit from RIPC. What was needed at this 
point was some larger randomised controlled trials to clearly define the role of 
RIPC in cardiac surgery. Two large-scale, prospective, randomized, sham-
controlled trials of RIPC have since been undertaken with results published 
after completing my own studies. Both studies delivered the same RIPC 
stimulus involving four cycles of 5 minutes ischaemia interspersed with 5 
minutes of reperfusion in anaaesthetised patients. The Remote Ischaemic 
Preconditioning for Heart Surgery (RIPHeart) Study comprised 1385 patients 
all deemed higher risk through pre-operative Euroscore assessment with an 
average score for all recruited patients being 4.2 (150). This study included a 
small number of patients that had ascending-aorta replacements as well as 
CABG and valve surgery. The results showed that RIPC did not reduce major 
adverse cardiac and cerebral events. In the Effect of Remote Ischaemic 
Preconditioning on Clinical Outcomes in Patients Undergoing Coronary Artery 
Bypass Surgery (ERICCA) trial recruitment totalled 1612 patients with a 
Euroscore of 5 or higher who were undergoing CABG with or without valve 
surgery (151). This trial, which was led by our institution also failed to show a 
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benefit in reducing major adverse cardiac and cerebral events assessed 12 
months after surgery. 
 
Another trial in progress is the (Effect of Remote Ischaemic Conditioning on 
Atrial Fibrillation and Outcome) RICO trial. This study is a randomised, 
controlled, double blinded muticentre study. Elective CABG patients will be 
randomised to one of the four following groups: 1) control 2) RIPC 3) RIPost 
or 4) RIPC and RIPost. The primary endpoint is the incidence of AF in the first 
72 hours after surgery detected using Holter monitoring and is looking to see 
a reduction of 40 to 50% by RIPC or RIPost or both. Some may question why 
AF as chosen as an endpoint but it is a strong predictor of outcome. 
Secondary endpoints are MACCE at 30 days 3 months and 1 year as well as 
length of stay in hospital and ICU. The benefits of investigating RIPost is that 
most ischaemic episodes such as acute coronary syndromes are actually 
unpredictable and therefore RIPC is not possible but RIPost may therefore 
have greater clinical implications (152).  A summary of the main trials in RIPC 
in CABG is in table 1, 2 and 3. 
 
Table 1: RIPC studies in CABG showing cardioprotection 
 
Author Year Patient 
cohort 
RIPC Protocol Outcome in RIPC 
group 
Gunayadin   2000 8 2x3 mins ↑LDH, CK-MB↔ 
Hausenloy  2007 57  3x5 mins ↓cTn AUC 72 hrs 
Venugopal  2009 45  3x5 mins ↓cTn AUC 72 hrs 
Thielmann  2010 53 3x5 mins ↓cTn AUC 72 hrs 
Ali  2010 100 3x5 mins ↓CK-MB 8,6,12,48 hrs 
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Wagner 2010 91 3x5 mins ↓cTn at 8hrs only. 
↔cTn at 16&24 hrs 
 
Hong 2010 130 4x5 mins ↓cTn AUC 72 hrs 
Krawczyk 2011 19 3x5 mins ↓cTn at 24 hrs 
Kottenberg 2012 72 3x5 mins ↓cTn AUC 72 hrs 
Hong 2012 70 4x5 mins ↓cTn AUC 72 hrs 
 
 
 
Table 2: RIPC studies in CABG failing to show cardioprotection 
 
Author Year Patient 
cohort 
RIPC Protocol Outcome in RIPC 
group 
Rahman  2010 162 3x5 mins ↔cTn AUC 72 hrs 
Karuppasamy 2011 54 3x5 mins ↔cTN AUC 48 hrs 
Lucchinetti 2012 55 4x5 mins ↑cTn AUC 72 hrs 
Hausenloy 2015 55 4x5 mins ↔cTN AUC 48 hrs 
Meybohm 2012 55 4x5 mins ↔cTn AUC 72 hrs 
 
 
 
Table 3: Latest RIPC studies in CABG looking at MACCE 
  
Author                   Year Patient 
cohort 
RIPC Protocol Outcome in RIPC 
group 
Thielmann  2013 329 3x5 mins ↓cTn AUC 72 hrs 
↓MACCE at 30 days, 
1yr and 1.58 yrs 
(median) follow up 
 
Hong  2014 1280 3x5 mins ↔ short term MACCE  
Hausenloy 2015 1612 4x5 mins ↔ 12 month MACCE  
Meybohm 2015 1385 4x5 mins ↔ 90 day MACCE  
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1.10.2 Remote ischaemic Conditioning in elective PCI 
One of the first trials in RIPC was by Iliodromitis et al. in 2006 and this looked 
at 41 consecutive normotensive patients with stable angina and single-vessel 
disease (153). RIPC was induced by three cycles of 5 minute ischaemia 
reperfusion of both upper limbs. Troponin [0.255(0.059) v 0.804 (0.232) ng/ml 
p<0.05] and CK-MB [1.33(0.27) v 3.57(0.97) ng/ml, p<0.01] was significantly 
increased in the RIPC group when compared to controls at 24 hours. 
Interestingly, a subgroup of patients on statins in the RIPC group had a 
significantly lower increase in troponin than those patients not on statins 
[23.8(3.71) versus 11.4(3.0) mg/l, p<0.01] which suggests that if RIPC 
induced an inflammatory response then statins may abate this. 
 
The Cardiac Remote IPC in coronary stenting (CRISP) study was a 
prospective, randomised controlled trial, which investigated RIPC in 242 
consecutive patients undergoing elective PCI (154). Patients were 
randomised to receive RIPC with the standard 3 cycles of 5 minutes forearm 
ischaemia and 5 minutes reperfusion. This study showed that RIPC reduced 
median troponin Ievels at 24 hours after PCI when compared to control. 
Subjects that received RIPC also experienced less chest discomfort 
(p=0.0006) and ECG ST segment deviation (p=0.005). At 6 months, the major 
adverse cardiac and cerebral event rate was also lower but not statistically 
significant. Notably the cardioprotection from RIPC was also seen in groups, 
which have previously shown to reduce the effect of preconditioning such as 
elderly patients, those with diabetes, hypertension and previous history of 
myocardial infarction. Longer-term follow-up at 6 years confirmed that the 
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reduction in MACCE was maintained by RIPC (155). Since the publication of 
this meta-analysis, the CRISP stent trial initially published by Hoole et al. and 
mentioned above has published its outcomes at 6 years after longterm follow 
up. MACCE was defined as all-cause mortality, nonfatal myocardial infarction, 
transient ischaemic attack or stroke and heart failure requiring hospital 
admission adjudicated by the medical notes and national database review. 
MACCE rate at 6 years remained lower in the remote IPC group (HR 0.58; 
95% CI, 0.35-0.97; p=0.039 ARR=0.13 and NNT=8) and in keeping with this 
mean troponin was elevated in the patients with MACCE. The investigators 
therefore concluded that RIPC conferred a MACCE-free survival benefit at 
both short and longterm follow-up (155). 
 
However, the CRISP investigators also applied the same RIPC protocol to 42 
patients with single vessel disease, which did not diminish the degree of LV 
dysfunction during coronary balloon occlusion, nor did it improve contractile 
recovery during reperfusion (156). Similarly, another study by the same group 
also published in 2009 failed to show an improvement in coronary 
microvascular resistance or coronary flow in humans from RIPC in elective 
PCI (157).  These finding showed promise but other studies in elective PCI 
showed varying results. Table 4 below summarises all the trials in elective 
PCI to date. The main problem with these studies has been that characterized 
by non-standardised protocols and had small numbers with recruitment from a 
single centre. Where these studies have been negative they have often had 
small numbers and so were underpowered or have had a very low ischaemic 
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stimulus which has been felt to be to too weak to produce a cardioprotective 
effect. 
 
Table 4. Main studies of Remote ischaemic conditioning (RIC) in elective PCI 
Author Year Patient 
cohort 
RIPC Protocol Outcome in RIC 
group 
Iliodromitis  2006 41 3x5 mins  
Both arms 
Before elective 
PCI 
↑cTn AUC 48 hrs 
↓cTN on statins 
Hoole 2009 242 3x5 mins 
Before elective 
PCI 
↓cTn at 24 hrs 
↓chest discomfort 
↓ST segment deviation 
↓MACCE but not 
significant 
Ghaemian 2012 80 2x5 mins 
Lower limb 
↓cTN  mean 
↔MACCE 
Prasad 2013 95 3x3 mins 
Upper limb 
↔cTN  mean 
Ahmed 2013 149 3x5 mins 
Upper limb 
↓cTN  at 16 hrs 
↔procedural MI 
Luo 2013 205 3x5 mins 
Upper limb 
↓cTN   
↓PCI-related MI 
Davies 2013 192 3x5 mins 
Elective PCI 
↓MACE short and 
longterm 
Liu 2014 200 3x5 mins 
Upper limb 
18 hrs before PCI 
↓median troponin  
↓MACE at 6 months 
Zografos 2014 94 1x5mins 
Upper limb 
↓median troponin  
↓PCI-related MI 
Xu 2014 200 3x5 mins 
Upper limb 
diabetics 
↔cTN 
↔PCI-related MI 
 
1.10.3 Remote ischaemic Conditioning (RIC) in PPCI and STEMI 
There are also a small number of studies looking at the role of RIC in STEMI 
patients and similarly the results of these studies are not consistent. Munk et 
al performed a randomised controlled trial in patients with first time 
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presentation of STEMI (158). Results suggested that RIPC during transfer for 
PPCI consisting of four 5-minute cycles resulted in no significant differences 
in LV function but there was a substantial improvement in left ventricular 
function in high-risk patients prone to developing large infarcts. In the subset 
of patients, having LAD infarcts there was preserved LV function at 1 day and 
1 month with significantly reduced LV volumes suggestive of decreased LV 
remodeling after RIPC. The results only being found in a subgroup led to 
criticism though that the effects had arisen by chance because of multiple 
testing. In addition, there was no data on LV function prior to infarction so the 
differences observed may have existed prior to the index event.  
 
Botker et al. used the same RIPC protocol in a study of 251 patients 
undergoing PCI for a first acute myocardial infarction. This study found that 
preconditioned patients had a greater myocardial salvage index assessed by 
single-photon emission CT (SPECT) after PCI compared with controls (0.75 
vs 0.55) at twenty days. Similarly, to the study by Munk et al. the effect was 
more robust in anterior infarcts and patients where vessels were totally 
occluded. However, left ventricular ejection fraction and troponin release were 
not significantly different between the two groups (159). 
 
Another study was by Rentoukas et al in 2010 which enrolled 96 patients 
undergoing PPCI and srandomised them to one of three groups, which were 
A) RIPC B) RIPC and morphine C) Control group. Upper arm ischaemia was 
achieved by inflating the cuff to >20mmHg systolic arterial pressure for three 
cycles each lasting 4 minutes with intervening reperfusion. A higher proportion 
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of patients in Groups A and B (73 and 82% respectively) achieved ST-
segment resolution after PCI when compared to controls (53%). Group B also 
achieved significantly lower troponin and ST segment deviation resolution. 
These findings demonstrated that overall RIPC and morphine demonstrated a 
cardioprotective effect, which is in keeping with the role of opioids in signal 
transduction in RIPC and is in keeping with the finding that IPC is blocked by 
the opioid antagonist naloxone (160). Criticisms of this study were that RIPC 
was performed using a new protocol that had never been  used before 
involving three cycles of 4 minutes as mentioned earlier with reperfusion 10 
minutes before the estimated time of first balloon inflation. Furthermore very 
little is known about clinical confounders such as age, comorbidity or co-
medication on the effectiveness of RIPC (161). 
 
Another study published in 2014 by Sloth et al. recruited 333 patients for 18 
months up until November 2008. This study randomised patients having 
STEMI and PPCI to remote ischaemic conditioning with 4 cycles of 5 minutes 
ischaemia followed by 5 minutes reperfusion. Patient follow up was for a 
median of 3.8 years and the primary endpoint was MACCE events. MACCE 
occurred in 17 (13.5%) in the intervention group compared with 32 (25.6%) 
patients in the control group. This study therefore reinforces RIPC as being of 
benefit in long-term clinical outcomes in patients treated with PPCI for STEMI 
(162). This study provides grounds for optimism but should be viewed with 
caution due to its size. 
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Yamanaka et al. published in 2013 performed a study with positive findings in 
favour of RIC (163). This study looked at RIC in 105 STEMI patients and used 
an automated blood pressure cuff to perform three cycles of 5 minutes 
alternating reperfusion and ischaemia. Although RIC had no effect on ST-
segment resolution, peak CPK values or MACCE during hospitalisation, there 
was a reduction in reperfusion arrhythmias after PCI and the incidence of 
contrast-induced nephropathy.  
 
A study from our own institution by White et al. randomly assigned 197 STEMI 
patients with a completely occluded artery (TIMI flow zero) to receive RIC 
consisiting of four cycles of 5 minutes of upper arm cuff inflation and deflation 
or control (164). Using cardiac magnetic resonance they showed that when 
patients were treated by RIC initiated prior to PPCI they reduced infarct size 
and oedema while increasing myocardial salvage by imaging 83 subjects 3 to 
6 days after admission.  
 
The LIPSIA trial by Eitel et al (165) investigated both RIC and IPost in STEMI 
patients. They evaluated whether intra-hospital RIC and IPost had a more 
powerful effect on myocardial salvage compared with either IPost alone or 
control. This prospective, controlled single centre study recruited 696 STEMI 
patients to these three groups and showed that myocardial salvage index 
assessed by CMR was significantly greater in the combined RIC and Post-C 
group (p=0.02). Clinical follow-up at 6 months revealed no significant 
difference in the combined clinical endpoints of death, reinfarction and new 
congestive heart failure (p=0.44).  
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Table 5. Main studies of Remote ischaemic conditioning (RIC) in PPCI 
 
Author Year Patient 
cohort 
RIPC Protocol Outcome in RIC group 
Botker 2010 251 4x5 mins 
Before PPCI 
↓cTN  at 90-102 hrs 
↑Myocardial salvage 
index by SPECT 
Rentoukas 2010 96 3x4 mins During 
PCI 
↓Peak cTn 
↓ST segment deviation 
↑ St segment resolution 
Munk 2010 242 4x5 mins 
Before PPCI 
↔LV function  
Subset of LAD infarcts 
had preserved LAD 
function with RIPC 
Sloth 2014 333 4x5mins 
Before PPCI 
↑MACCE at median of 
3.8 yrs 
Yamanaka 2014 109 3x5mins 
Before PPCI 
↔ST resolution 
↔CPK levels 
↔MACCE 
↓reperfusion arrhythmia 
↓CIN 
White 2015 333 4x5mins 
Before PPCI 
↓myocardial infarct and 
oedema 
 
Yetgin et al. (161) have provided an overview of the current state of play 
regarding RIC in PCI with their meta-analysis. Notably they analysed data 
from trials of elective PCI and PPCI. They found that there was no significant 
decrease in myocardial injury biomarkers although the trend was towards a 
cardioprotective effect with RIC. They also found that the greatest decrease in 
cardiac biomarkers in patients receiving RIC during PPCI with no presence of 
heterogeneity. When excluding the Iliodromitis et al. study there was 
significant pooled data standardised mean differences in favour of RIC. The 
use of both arms to apply RIC may in part, have explained the neutral results 
of this study. Notably subgroup analysis of trials seemed to indicate that the 
most benefit from RIC in PCI was reached when there was a large myocardial 
area at risk from the index ischaemia. If results show that RIC is of prognostic 
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benefit then this will enable the routine use of a simple, cheap and low-risk 
intervention to further benefit patients. The CONDI2/ERIC-PPCI trial is 
currently underway to investigate the prognostic benefit of RIC following 
PPCI. 
 
1.11 Diabetes 
1.11.1 Background 
In the UK, diabetes mellitus (DM) has a prevalence of 4.7% and affects 
around 3 million people. This has risen sharply from 1.9 million in 1996 and is 
expected to reach 5 million by 2025 in the UK (166) and worldwide an 
expected 300 million (167). The increase in this figure has been attributed to 
the fact that the population is becoming increasingly aged, more sedentary 
and there is a rise in obesity. The metabolic cause of DM is a combination of 
insulin resistance in the periphery as well as a deficiency of insulin secretion 
by pancreatic B cells. Insulin resistance develops from being overweight and 
physical inactivity and is coupled with genetic susceptibility. The decline in 
insulin secretion also has a genetic basis but mainly declines with increasing 
age (168). As well as this diabetes often coexists with other cardiovascular 
risk factors such as hypertension and hypercholesterolaemia. The 
complications of diabetes are many and include coronary heart disease, 
stroke, peripheral arterial disease, nephropathy, retinopathy and possible 
neuropathy and cardiomyopathy. Of these, cardiovascular morbidity and 
mortality is perhaps the most serious with a significantly higher mortality in 
these patients from acute myocardial infarction due to more extensive 
atherosclerotic lesions, diffuse disease and also a hypertrophied and 
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dysfunctional left ventricle (169). Rates of re-infarction and heart failure after 
the first acute myocardial infarction are also higher as well as the incidence of 
multivessel disease in DM (170, 171). Haffner et al. showed that 
cardiovascular event risk in diabetic patients with no history of infarction was 
the same as those seen in non-diabetic patients with prior myocardial 
infarction (172). From large scale trials it is recognised that chronic glycaemic 
control is unlikely to play a role in modulating mortality from myocardial 
infarction and so the risk from diabetes is absolute (173). Therefore, there is 
an opportunity to develop novel strategies for cardioprotection from IR injury 
in DM patients. 
 
1.11.2 The myocardium in diabetes 
The results of infarct size studies in diabetic animal models have been 
contradictory, and the reason for differences remains unclear. There exists 
controversy as to whether the diabetic heart is more or less susceptible to 
myocardial IR injury. However, clinical studies have shown that there is an 
increased myocardial susceptibility to IR injury (174). 
 
Studies in animal models have shown that infarct size in diabetic models have 
never varied in comparison to non-DM patients. Animal models have included 
rat, mice, dog and rabbit with rodents being the most popularly studied 
because of the ability to inbreed and reproduce quickly with inherited diabetes 
and obesity.  Infarct size has been similar, smaller, or larger in DM animals 
and the reasons for this have not been fully understood, but there has always 
been a significant difference in experimental preparations and protocols. The 
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duration of diabetes appears to influence myocardial tolerance against 
infarction and experiments have therefore yielded different results between 
the two. For example in a study by Ravingerova et al., type I DM was induced 
by injection of streptozotocin (STZ) into rats which is a toxic glucose analogue 
that accumulates in pancreatic B cells thereby rendering them inactive. 
Infarcts were induced by 30 minutes ischaemia but notably infarct size 
limitation was seen at 1 week but not later at 8 weeks (175). This has been 
reinforced by other studies which have shown the resistance of diabetic 
hearts to IR injury was seen in the early phase of DM but disappeared with 
time (176) but has also been contradicted by studies that have shown 
enlargement of infarct size at around 1 week after STZ injection (177). This all 
indicates that duration of diabetes is not the only factor responsible for these 
inconsistencies. Possible explanations include other co-existent unfavourable 
metabolic states such as dyslipidaemia. Other factors for consideration also 
include whether studies used low-flow ischaemia or zero-flow ischaemia, 
which have different effects on glycolysis, acidosis and lactate production and 
other metabolism within myocardial cells (178). 
 
A clinical study by Marso et al in 2007 of 501 patients of which 62 (12%) has 
shown increased myocardial damage in infarction determined by technetium-
99m single proton emission computed tomography (SPECT) imaging after 
reperfusion therapy. As well as this, there was greater development of heart 
failure, 30-day mortality, 6-month mortality and impaired myocardial perfusion 
evidenced by blush grade in diabetic patients (174). A study by Algeria et al. 
in the same year enrolled 2948 patients that underwent SPECT and 6-month 
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follow up. This study found a slightly larger infarct size in the diabetic cohort of 
patients and a slightly poorer ejection fraction. There was a substantially 
increased risk of mortality by 4 to 6-fold in diabetic patients but this was not 
explained by the small changes in infarct size and implied that DM itself, 
associated co-conditions or diabetic cardiomyopathy played a significant role 
in risk (179).  Ruber et al. first introduced diabetic cardiomyopathy as a term 
30 years ago when he described four patients with heart failure and normal 
coronary arteries (180).  Several factor probably underlie diabetic 
cardiomyopathy and these are coronary atherosclerosis, prolonged 
hypertension, chronic hyperglycaemia, microvascular disease, glycosylation 
of myocardial cell proteins and autonomic neuropathy (178). At a cellular 
level, potential contributors are reduced glucose and lactate metabolism with 
increased free fatty acids activating PPAR-α signalling leading to the 
transcription of genes that modulate fatty acid oxidation.  This leads to the 
formation of ROS at the level of the electron transport chain. ROS, which can 
also be generated by extramitochondrial mechanisms such as NADPH 
oxidase plays a critical role in several pathways thought to mediate diabetic 
cardiomyopathy. These include toxicity from lipids, cell death and 
mitochondrial uncoupling (183). 
 
1.11.3 Defects in intracellular signalling in diabetic hearts 
Experimental and clinical studies have both shown that diabetes interferes 
with the cardioprotective strategies of preconditioning and postconditioning. 
The majority of these studies have shown that diabetes interferes with the 
protective signalling pathways involved in cardioprotection that all appear to 
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converge on the mPTP. Experimental studies have shown that the infarct 
limiting size effect of IPC or IPost was lost or diminished in DM or may require 
an increased stimulus. The Yellon group showed that one, two and three 
cycles of IPC entailing 5 minutes of global ischaemia followed by 10 minutes 
of reperfusion each resulted in cardioprotection when infarction was induced. 
However in type 2 DM Goto-Kakizaki (GK) rats, only 3 cycles of IPC 
cardioprotected from the infarction protocol of 35 minutes regional ischaemia 
followed by 120 minutes reperfusion (182). This strongly suggested that the 
threshold for stimulating IPC in diabetic hearts needed to be increased. 
Impairment of preconditioning in DM has been observed across the board 
with species to include rats, rabbits and dogs and using different models of 
diabetes such as type I DM (STZ rats) and type 2 DM genetic rodent models 
(OLETF, GK, db/db, Zucker diabetic fatty rats (ZDF) and ob/ob mice).  
 
Various mimetics of IPC and IPost have confirmed that intracellular signalling 
is impaired in DM by being ineffective at limiting infarct size in diabetic hearts 
and these include diazoxide, erythropoeitin and isoflurane (183). Other steps 
involved in cytoprotective signalling have also been impaired or blocked by 
DM. For example, PI3K/Akt was shown to be defective in DM resulting in less 
AKT phosphorylation, which was shown in the same study performed by our 
group mentioned above (183). As well as this, other mediators such as ERK 
and STAT3 and other various components of the RISK pathway have also 
been shown to be impaired (184). As mentioned previously GSK-3β has been 
considered a pivotal step in IPC and IPost cardioprotection. Studies have 
shown that as well as RISK inactivation that diabetes induced GSK-3β plays a 
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crucial role in diabetic myocardial oxidative damage and remodelling. Indeed 
some studies have reported that GSK-3β activity is doubled in diabetes (185). 
Various studies have also looked at whether hyperglycaemia itself has a role 
in cardioprotection afforded from IPC or IPost. Acute hyperglycaemia either 
made no difference or resulted in impaired protection such that infarct size 
limitation was reduced. This was also seen in other studies using other 
conditioning stimuli such volatile anaesthetics and K+ channel openers (186).   
 
In various human studies, it has been shown that those patients with pre-
infarct angina had reduced infarct size determined by CK release, improved 
left ventricular function and reduced mortality and a better prognosis (187). 
Pre-infarct angina is recognised as a natural form of IPC. However, in patients 
with DM these benefits were not seen suggesting an attenuated response to 
IPC in these patients (188). In vitro experiments by the Yellon group who 
established this technique using atrial trabeculae have further supported this 
finding using atrial trabeculae taken at the time of cardiac surgery, which has 
shown contractile dysfunction after hypoxia and reoxygenation to be 
significantly suppressed by preconditioning but not in diabetic hearts (189). To 
restore cardioprotection in diabetic tissue the ischaemic stimulus needed to 
be increased from 4 minutes to 7 minutes and was also associated with a 
downregulation of PI3K/Akt axis. Similarly prior to this Ghosh et al. showed 
the failure of IPC to protect the diabetic human myocardium using right atrial 
appendage with one 5 minute cycle of ischaemia followed by one 5 minute 
cycle of reperfusion (190). 
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1.11.4 Diabetic medications and preconditioning 
A hot topic for some time has been whether sulphonylureas result in adverse 
effects on diabetics. In the UGDP study published in the 1970s there was an 
increased mortality in patients taking tolbutamide (191). These drugs have 
been shown to inhibit protection from IPC and IPost by blocking the KATP 
channel in cardiac myocytes raising concerns that sulphonylureas may be 
detrimental in myocardial infarction, however, the effects of different 
sulphonylureas are not the same in IPC and IPost. Glibenclamide a non-
specific KATP blocker and has been found to block effects of IPC and IPost in 
non-diabetic animals (192). However, Nieszner et al. reported the restoration 
of the infarct sparing effect of preconditioning with low does glibenclamide in 
type I DM alloxan-treated rabbits. This was not seen with high dose 
glibenclamide. The postulated mechanism is that the benefit of glibenclamide 
was due to tight glycaemic control possibly influencing PI3K/Akt signalling 
which could override the partial inhibition of cardiac KATP channels (193). 
 
Glimepiride showed the reverse effect of glibenclamide when tested by the 
Yellon group. Glimepiride a second-generation sulphonylurea was reported to 
affect the non-pancreatic KATP channels less than glibenclamide. This study 
looked at normal rat hearts and showed that glimepiride did not block the 
infarct-size limiting effects of IPC by not inhibiting the beneficial effects of 
mitochondrial KATP channels in the heart (194). Similar results were seen with 
intravenous infusion of glimepiride in a double-blind placebo controlled study 
of humans during PCI. This study also reinforced the potential of 
glibenclamide to block preconditioning (195). In rabbit myocardium, 
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glimepiride infusion during reperfusion was shown to have an IPost-mimetic 
effect by activation of PI3K/Akt (196). Notably these few studies have been 
performed in non-diabetics as IPC and IPost have failed to show an infarct-
limiting effect in DM. 
 
Metformin is an insulin-sensitising agent that reduces hepatic glucose 
production and increases peripheral uptake. In a study by Ye et al. metformin 
reduced infarct size by activation of AMP-activated protein kinase (197). The 
infarct size-limiting effect of metformin remains highly controversial with 
conflicting results from two studies (198, 199). One of these studies was 
performed by our group and showed that metformin given during reperfusion 
protected myocardium during infarction in diabetic and non-diabetic hearts 
and this was mediated by PI3/Akt and inhibited mPTP opening (199). 
Kravchuk et al. found that infarct size was reduced in type 2 DM rats and 
metformin did not induce a cardioprotective effect in an IR model (198). This 
result is not in keeping with metformin’s known beneficial cardiovascular 
effects in humans. 
 
Pioglitazone and Rosiglitazone are Thiazolidinediones administered before 
ischaemia and were both found to reduce infarct size in normal and diabetic 
animals. However, the impact of the cardioprotective effect of 
thiazolidinediones on clinical benefit and adverse events is unclear with 
Rosiglitazone having been shown to increase the risk of myocardial infarction 
and Pioglitazone appearing to reduce cardiovascular events. It is speculated 
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that this is because of the differing properties and specificities for these drugs 
on the peroxisome proliferator-activated receptor (PPAR) receptors (199). 
 
Recently glucagon-like peptide (GLP-1) receptor agonists and inhibitors of 
dipeptidyl peptidase-4 (DPP-4) inhibitor have demonstrated clinical 
cardiovascular benefits. However, there is little data on the effects of these 
two drugs on IR injury (200). One study by Huisamen et al (201) has reported 
that enlargement of infarct size in obese pre-diabetic rats was decreased at 4 
weeks by treatment with a DPP-4 inhibitor. Our group have shown that the 
active metabolite GLP-1(7-36) can limit infarct size by decreasing IR injury in 
isolated and in-situ rat hearts when given with a DPP-IV inhibitor [which 
prevents the breakdown of active GLP-1(7-36) to GLP-1(9-36)] before IR 
(202). It has also been shown to protect against myocardial IR injury when 
given as a preconditioning-mimetic or at reperfusion (203). Interestingly a 
study using pigs failed to show a benefit with GLP-1 but this study was carried 
out without co-administration of a DPP-IV inhibitor (204). Interestingly these 
initial studies described above suggest a beneficial effect in non-diabetic and 
diabetic patients. Further studies of these drugs are required on intracellular 
protective signalling and their beneficial cardiovascular effects (205). 
 
1.11.5 Diabetes and cardioprotection 
In summary, it appears that DM increases myocardial susceptibility to IR 
injury through various mechanisms, which results in worse outcomes for 
diabetic patients in the context of myocardial infarction. DM also changes the 
response of myocardium to IPC and IPost by disruption of signalling cascades   
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involved in cardioprotection. At a cellular level cardioprotection may occur 
through manipulation of mechanisms upstream from GSK-β and mPTP or 
blockade of mPTP opening. Preconditioning appears to be a potential 
mechanism for affording cardioprotection potentially through altering 
cytoprotective signalling but this may only be realised with an increased 
preconditioning stimulus. 
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Chapter 2: Aims and Hypotheses 
2.1 A study of RIPC in cardiac bypass patients with diabetes in our 
institution 
A previous study at our institution investigating three cycles of arm RIPC (5 
minutes ischaemia with 5 minutes reperfusion intervals) did not show benefit 
in a diabetic cohort of CABG patients. However, when the RIPC stimulus was 
intensified by using simultaneous inflation/deflation of cuffs placed on upper 
arm and leg, there was a cardioprotective effect but only 35 patients were 
recruited. In my thesis, I have added patients to this cohort. 
 
2.1.1 Aims 1 
To further evaluate the role of RIPC in diabetic CABG patients using 2 cycles 
of simultaneous leg and arm RIPC in a sufficient sample size to provide 
adequate statistical power.  
 
2.1.2 Hypothesis 1: 
Increasing the intensity of the RIPC stimulus will confer cardioprotection in 
diabetic patients undergoing CABG surgery. 
 
2.2 A study of RIPC in cardiac surgery patients that received 
intravenous GTN at our institution 
A retrospective analysis of 180 patient cohort suggested that those patients 
receiving IV GTN were not cardioprotected by two cycles of 5 minutes 
ischaemia and 5 minutes reperfusion with simultaneous arm and legs RIPC. 
In 2014, our institution began a study to determine whether GTN reduces 
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injury to the heart during heart-lung bypass surgery in combination with the 
newer technique of RIPC. This is called the Effect of Remote IPC and 
Glyceryl Trinitrate on Peri-operative Myocardial Injury in Cardiac Bypass 
Surgery Patients (ERIC-GTN Study). There are four arms in this study with a 
control group receiving Sham Remote IPC (RIPC) with IV normal saline 
infusion.  Patients will also be administered an RIPC protocol of three 5 
minute cycles of ischaemia with intervening reperfusion with simultaneous 
upper arm and thigh cycles prior to surgery. A third group will receive GTN 
and sham simulated RIPC at 2-5 ml/hr during surgery. A fourth group will 
receive RIPC and IV GTN. By increasing the stimulus to three cycles of multi-
limb RIPC but with the same protocol I hope to see whether this will result in 
cardioprotection in those patients receiving IV GTN. 
 
2.2.1 Aims 2 
To evaluate whether an increased stimulus of 3 cycles of simultaneous arm 
and leg RIPC overcomes the potential effect of confounding factors such as 
administration of intravenous GTN and provides further myocardial 
preservation to those patients receiving RIPC where it had not been seen 
previously at the lower 2 cycle RIPC stimulus.  
 
2.2.2 Hypothesis 2: 
Increasing the intensity of the RIPC stimulus will confer cardioprotection in 
patients undergoing CABG surgery who are administered IV GTN. 
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Chapter 3: General Methodology 
3.1.1 Experimental design 
The two main clinical studies in diabetics patients and in the presence of GTN 
were already designed originally in 2001 and various amendments had been 
made over the years by investigators at our institution because of variations in 
their study. I therefore provided the amendments to the previous study 
protocol and obtained ethical approval for these changes. The specific 
amendments for each study are described in their individual results chapter. 
Below is the general methodology which was generic for both studies. 
 
3.1.2 Inclusion criterion 
a. Age more than 18 years old. 
 
b. Patients undergoing CABG surgery and/or valve surgery at the Heart 
Hospital at University  
 
c. Patient to be given informed consent with an information sheet which 
should ideally be given 24 hours prior to agreement to participate. 
 
d. The current WHO diagnostic criteria for diabetes was used to see if 
patients fulfilled the criterion for being diagnosed with having diabetes. 
Patients needed to have a fasting plasma glucose ≥ 7.0mmol/l 
(126mg/dl) or 2–h plasma glucose ≥ 11.1mmol/l (200mg/dl. Although it 
is understood that there are limitations with this definition the current 
criteria distinguish a group with significantly increased premature 
mortality and increased risk of microvascular and cardiovascular 
complications.  
 
3.1.3 Exclusion criterion 
a) Cardiogenic shock or cardiac arrest preceding surgery where 
cardiogenic shock was defined as systolic BP <90mmHg for 30 
minutes before inotrope/vasopressor administration or an intra-aortic 
balloon pump (IABP) was used to maintain systolic BP>90mmHg. 
 
73 
 
b) Positive baseline serum hsTnT and/or CK-MB as these patients may 
already be preconditioned by a recent event with a subsequent 
potential impact on RIPC prior to cardiac surgery. 
 
c) Pregnancy. 
 
d) Significant peripheral artery disease affecting any of the limbs.  
 
e) Significant liver dysfunction with an International Normalised Ratio 
(INR) greater than 2.0. 
 
f) Significant pulmonary disease with a Forced Expiratory Volume of less 
than 40% predicted. 
 
g) Renal failure with an estimated glomerular filtration rate (eGFR) 
<30ml/min/1.73m2 as troponin excretion via the kidney is altered in the 
presence of kidney disease thereby making hsTnT evaluation 
unreliable. 
 
h) Concomitant therapy with glibenclamide or nicorandil as these 
medications may interfere with RIPC. 
 
3.1.4 Randomisation 
Randomisation was carried out on the day of surgery as soon as patients 
were sent to the theatres for anaesthesia. Randomisation was carried out 
using a free online tool, which randomly allocated patients to either control or 
intervention arms. 
 
3.1.5 Intervention: RIPC and sham treatment protocols 
RIPC and control protocols were applied after anaesthesia induction and prior 
to transfer to theatre for draping. RIPC was delivered with a standard arm BP 
cuff placed on the contralateral arm where the arterial line was sited and a 
standard thigh BP cuff. The cuffs were simultaneously inflated to 200mmHg 
and then left inflated for 5 minutes. They were then deflated to 0mmHg and 
left deflated for 5 minutes. This cycle was repeated three times so that the 
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total duration of the intervention was 30 minutes. For the control protocol the 
two cuffs were simultaneously placed on the upper arm and the upper thigh 
and left uninflated for 30 minutes. 
 
3.1.6 Anaesthetic procedure 
Patients received pre-medication with oral temazepam 10 to 20mg 
approximately one hour prior to surgery. The patient was then taken the 
anaesthetic room where IV access was gained through a peripheral venous 
cannula a central venous and continuous invasive BP monitoring was 
achieved with the insertion of an arterial line. Anaesthesia induction was 
obtained with a combination of midazolam, etomidate, propofol, fentanyl, 
rocuronium, vecuronium, or pancuronium. Following anaesthesia induction 
the trachea was intubated and mechanical ventilation commenced with 
oxygen with or without air. Anaesthesia maintenance was achieved with 
volatile anaesthetic agents including isoflurane or sevoflurane and propofol 
infusion with or without fentanyl. Intravenous glyceryl trinitrate infusion (GTN) 
was administered at the discretion of the anaesthetist in order to optimise BP 
control and improve intraoperative coronary vasodilatation. 
 
3.1.7 Surgical procedure 
Following anaesthesia and either RIPC or sham protocols the patient was 
transferred to theatre where mid-line sternotomy was performed. Standard 
non-pulsatile cardiopulmonary bypass (CPB) was performed using a 
membrane oxygenator and cardiotomy suction with cannulation of the aortic 
root and the right atrial appendage: for coronary artery bypass surgery the 
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proximal end of each vein graft anastomosis was created during CPB with the 
distal end to the coronary arteries being constructed during cardiac standstill 
which was achieved through either injection of cardioplegic solution or 
induction of ventricular fibrillation with aortic root cross clamp. Ventricular 
fibrillation was induced through the application of an alternating current to the 
epicardium following clamping of the aortic root and was reverted using a 
direct current shock. 
 
Cardioplegic myocardial preservation was achieved through two different 
methods. 
1) Antegrade cardioplegia: 1 litre of cold blood cardioplegic solution (1 
part of St John’s Cardioplegia solution mixed with 4 parts of cold blood) 
was delivered to myocardial cells through the aortic root further to 
aortic cross-clamp followed by a maintenance cold blood cardioplegia 
which was given down the grafts in occluded arteries and also into the 
aortic root every 20 to 30 minutes. Systemic temperature in these 
patients was 28-34 C. 
2) Antegrade and retrograde cardioplegia: an initial 800ml dose of 
antegrade cardioplegia was administered into the aortic root followed 
by 400mls of retrograde cardioplegia solution given through the 
coronary sinus. Following each anastomosis maintenance was 
achieved with a further administration of 100mls of retrograde 
cardioplegia. On completion of the anastomosis CPB was discontinued 
and rewarming was initiated and protamine was given to reverse any 
heparin. 
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3.1.8 Baseline characteristics for intravenous GTN 
Both groups matched well and had no significant differences between the 
baseline characteristics. 
 
3.1.9 Statistical analysis 
Standard statistical methods were used for analysis with comparison between 
the sham and intervention groups being made using unpaired Student-T test 
for approximately distributed variables or Wilcoxon-Mann-Whitney test for 
non-normal data and categorical data using the Chi-square test. For 
outcomes collected at different time points a repeated measures linear 
regression model was used to estimate the difference at each point and 95% 
confidence intervals. The post-hoc analysis of associations between RIPC 
and intravenous GTN was performed using an interaction test in a linear 
regression model.  
 
3.1.10 Imputation of missing values 
Data sets that had missing troponins at time point 0 or 72 hours had to be 
excluded. This totalled 9 patients or 10% of the total recruited. I then excluded 
6 (8%) of patients that had more than 2 troponin values missing from time 
points 6, 12 ,24 and 48 hours as no meaningful analysis could be performed. 
For those that remained 7 patients (11%) had two time point values missing 
and 11 patients (17%) had had a single value missing. Using SPSS missing 
values software the multiple imputation procedures provided analysis of 
patterns of missing data and multiple imputation of missing values. Multiple 
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versions of the dataset were produced each containing its own set of imputed 
values. When statistical analyses were performed, the parameter estimates 
for all of the imputed datasets were pooled providing estimates that are 
generally more accurate than they would be with only one imputation. For 
unbiased results it is essential that the assumption that missing data is 
completely at random which should be the case here. 
 
3.2 Study endpoints 
3.2 Primary endpoint 
 3.2.1. Periprocedural myocardial infarction (PMI) 
This was periprocedural myocardial infarction or PMI measured by total area-
under-the-curve (AUC) of the total release of hsTnT over the 72 hours pours 
operatively using 0, 6, 12, 24, 48 and 72 hour blood troponin samples being 
taken. My research predecessor showed that an increased stimulus of RIPC 
of 2 cycles of simultaneous arm and leg ischaemia for 5 minutes afforded 
significant cardioprotection but not in the presence of patients that received 
intravenous GTN (3). We therefore intended to establish whether an 
enhanced RIPC stimulus of 3 cycles would reduce periprocedural myocardial 
infarction and overcome confounding factors such as f those patients that had 
received intravenous GTN. HsTnT was measured using the one-step enzyme 
immunoassay based on electrochemiluminescence technology (Elecsys 2010, 
Roche, Switzerland). Study primary end-point: PMI. The threshold level of 
0.0014 ug/L was cut off for the indication of significant myocardial necrosis 
and was the 99th centile for the reference population with a risk of <10%. 
 
78 
 
Absolute hsTnT release over the 72 hour post-operative period was 
calculated with AUC using the following Excel office 2010 formulas: 
1) AUC between two specific time-points (for example time-points 1 and 
2): 
AUC t1-t2 = [(hsTnT at t1 hours + hsTnT at t2 hours)/2] x (t2-t1) 
2) Total AUC over the post-operative 72 hours: 
AUC-72 hours=AUC0-6+AUC6-12+AUC12-24+AUC24-48+AUC48-72 
 
3.3 Study secondary endpoints 
3.3.1 Acute Kidney Injury (AKI) 
In the context of cardiac surgery AKI can occur in up to 30% of patients and 
impairs the function of other organs such as the brain, lungs and gut. The risk 
of death is increased by 5-fold during hospitalization. Around 2-5% of patients 
following cardiac surgery need renal replacement therapy and this causes a 
steep rise in mortality of up to 50% (206). Preventative strategies are limited 
and centre around maintain renal perfusion and metabolism and so RIPC 
could potentially lend itself to benefit in this area. Acute Kidney Injury is the 
abrupt loss of kidney function resulting in the retention of urea and other 
nitrogenous waste products and in the dysregulation of extracellular volume 
and electrolytes. For the purposes of this study AKI was derived using an AKI 
score over the first 3 post-operative days through looking at serum creatinine 
and urine output. AKI score as modified from Rifle’s criteria (207 and 208) 
with creatinine measure at 0, 24, 48 and 72 hours and urine volumes 
measured at 24,48 and 72 hours. 
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Table 6. Rifle’s criterion for AKI 
AKI Grade Creatinine criteria Urine output criteria 
1 Creatinine rise >26.4 µmol/L or 150-200% 
baseline 
<0.5ml/kg/hr for >6 hours 
2 Creatinine rise 200-300% of baseline <0.5ml/kg.hr for >12 hours 
3 Creatinine rise>300% or >354 umol/L with 
an acute rise of at least 44 umol/L 
<0.3ml/kg/hr for >24 hours 
or anuria for 12 hours. 
 
3.3.2 Inotrope requirements 
The amount of cardiovascular support in the first 72 hrs after heart surgery 
with cardiopulmonary bypass predicts eventual mortality and morbidity (209, 
210). The degree of support is best characterised by a maximum vasoactive-
inotropic score adapted from a score by Ko et al.(211) and provides an 
objective measurement of the requirement of inotropes in the immediate 
postoperative period. Data was collected every 24 hours for as long as the 
patients were on inotropes and calculated using the formula below. 
 
Inotrope score=Dosages (in ug/kg/min) of: 
[Dopamine + Dobutamine + Dopeximine] + [(Adrenaline + 
Noradrenaline + Isopreterenol) x 100] + [(Enoximone + Milirinone) x15]. 
 
The inotrope score was calculated for time ‘0’ for the dose of individual 
inotropes used at the time of coming off bypass and the other time 
points used the maximum dose of individual inotropes used in the 
previous 24 hour period.  
 
3.3.3 Intensive Care Unit (ICU) and hospital stay 
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Post-operatively all patients had a planned admission to ICU as this is 
recognised to reduce morbidity and mortality (212). Increased lengths of stay 
of these two parameters is known to be associated with more ‘adverse’ peri-
operative conditions such as longer anaesthesia, cardiopulmonary bypass 
and postoperative intubation time (213). Lengths of stay were therefore 
collected to see if RIPC had any impact on burden. The length of ICU and 
hospital stay was taken as the total number of days from operation to transfer 
or discharge respectively. ICU stay was counted up to when it was clearly 
documented in the notes that transfer was appropriate as this was often 
delayed due to beds not being available. Similarly hospital stay was counted 
up to the date where it was clearly documented that discharge was 
appropriate as frequently there were delays because of hospital inefficiencies 
or social reasons. 
 
3.3.4 New onset of post-operative AF 
New onset of post-operative AF occurs in up to 33% of patients undergoing 
coronary artery bypass surgery (214) and is even higher in those that have 
had valve surgery. Post-operative AF is associated with an increased risk of 
stroke and thromboembolism as well as greater morbidity and mortality (215). 
We therefore collected data on incidence of new AF to see whether AF may 
protect patients from this arrhythmia. An episode of new AF was counted as 
any episode noted by telemetry or ECG that required treatment by 
pharmacological intervention or direct current cardioversion. Patients with 
known permanent AF or paroxysmal AF were excluded from the evaluation of 
the secondary end-point. 
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Chapter 4 – Results for RIPC in a diabetic cohort of patients 
undergoing cardiac surgery 
 
4.1 Introduction 
4.1.1 A study of RIPC in cardiac bypass patients with diabetes in our 
institution 
We have shown in our institution that three cycles of 5 minutes of upper limb 
RIPC cardioprotected in an unselected cohort of patients undergoing cardiac 
surgery, however this effect was not seen in a susbsequent study of diabetic 
patients. A total of 60 patients with type 2 diabetes completed this later study 
over a two year period. 30 patients were in the RIPC group and 30 in the 
control group. Both groups were well-matched in terms of baseline 
characteristics and intra-operative parameters. With three cycles of upper limb 
ischaemia there was no statistical difference in mean cTnT levels between the 
RIPC group and control groups at any time point collected over 72 hours. The 
mean cTnT AUC over 72 hours in the control group was 24.55 ug/L with the 
RIPC group value being 22.38 ug/L which gave rise to p=0.52. Similarly, there 
was no difference between post-operative ventilation times (7.74 hours control 
group vs. 7.93 hours RIPC group, p=0.87), post-operative ITU stay (2.77 days 
control vs. 2.8 days RIPC group, p=0.98), post-operative inotrope score (7.4 
ug/kg min control group vs 9.98 ug/kg/min RIPC group, p=0.55), post-
operative atrial fibrillation (6 patients control group vs 4 patients in the RIPC 
group, p=0.73) and post-operative acute kidney injury (4 patients control 
group vs. 2 patients in the RIPC group p=0.67). 
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As discussed earlier, in diabetic hearts the myocardium behaves differently in 
relation to IR injury and this is felt to be through differences in metabolism or 
intracellular signalling when compared to normal myocardium. The RIPC 
effect is either attenuated or to achieve cardioprotection a greater stimulus is 
needed in the diabetic heart. This study looked at an intensified RIPC stimulus 
using two cycles of 5 minutes simultaneous inflation and then 5 minutes of 
deflation of cuffs placed on upper arm and leg. This multi-limb RIPC is in 
effect an increase of one cycle in those patients that had undergone 3 upper 
limb cycles. 48 patients in total were recruited in this cohort with 23 in the 
control group and 25 patients in the RIPC group. My predecessor had 
recruited 36 patients and I added 12 further patients to this cohort with 6 in the 
control group and 6 in the RIPC group. 
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Figure 4.1 Study profile for cohort of diabetic patients recruited and 
added to a predecessor’s study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
449 patients screened for eligibility in total.  
217 recruited into other studies 
 
 
 
 
 
181 fulfilled exclusion criterion 
 
3 patients excluded as 0 and 72 hour timepoint values missing 
 
3 refused to participate  
48 patients randomised 
25 patients randomised to control and 26 patients randomised to RIPC  
25 patients randomised to RIPC 
 
23 patients control 
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Table 7. Baseline characteristics in patients undergoing cardiac surgery and 
randomised to either sham or two cycles of 5 minutes of upper and lower limb 
ischaemia and reperfusion 
 
Patient Characteristic 
DM cohort 
Control (n=23) 
  
  RIPC (n=25) 
   
 
Age (years) 
Gender  
Male 
Female 
 
Ethnicity 
Caucasian 
Asian 
Turkic 
Middle-Eastern 
 
Body Mass Index 
 
Smoking history 
Smoker 
Ex-smoker 
Non-smoker 
 
Co-morbidities 
Hypertension 
Hypercholesterolaemia 
Atrial Fibrillation 
Previous MI 
Previous CVA/TIA 
Previous cardiac surgery 
 
LVEF 
>50% 
30-50% 
<30% 
 
NYHA 
 
CCS 
 
Family History of IHD 
 
Euroscore 
 
Bypass time (mins) 
 
Cross-clamp time (mins) 
 
71±9 
 
18 (78%) 
5 (22%) 
 
 
15 (65%) 
3 (13%) 
3 (13%) 
2 (9%) 
 
28.2±5.9 
 
 
5 (22%) 
15 (65%) 
3 (13%) 
 
 
20 (87%) 
19 (83%) 
3 (13%) 
6 (26%) 
1 (4%) 
0 
 
 
22 (96%) 
1 (4%) 
0 
 
2.2±0.9 
 
2.6±0.8 
 
15 (65%) 
 
3.59±1.67 
 
82.4±38.2 
 
60.5±22.7 
 
66±8 
 
16 (64%) 
 9 (36%) 
 
 
18 (72%) 
6 (24%) 
0 (0%) 
1 (4%) 
 
29.9±4.7 
 
 
7 (28%) 
16 (64%) 
2 (8%) 
 
 
18 (72%) 
20 (80%) 
3 (12%) 
9 (35%) 
2 (8%) 
0 
 
 
23 (92%) 
2 (8%) 
0 
 
2.5±0.7 
 
2.3±0.9 
 
16 (64%) 
 
3.22±1.92 
 
84.8±33.8 
 
68.4±18.3 
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Patient Characteristic Control (n=23)   RIPC (n=25) 
Drug history 
Aspirin 
Clopidogrel 
Prasugrel 
Ticagrelor 
Warfarin 
Beta-blocker 
Calcium channel blocker 
Statin 
Ace-i/A2RB 
Long acting nitrate 
Nicorandil 
Insulin 
Biguanide 
Sulphonylurea 
Thiazolidinediones 
Diuretics 
 
Cardioprotection 
Blood cardioplegia 
Cross-clamp fibrillation 
 
Operation 
CABG 
AVR 
MVR or repair 
CABG+AVR 
 
Grafts 
1 
2 
3 
4 
 
Anaesthetic agents 
Induction 
Rocuronium 
Pancuronium 
 
Propofol 
Fentanyl 
Etomidate 
Midazolam 
 
Maintenance 
Propofol 
Isoflurane 
Sevoflurane 
 
Intra-operative Glyceryl 
trinitrate 
 
20 (87%) 
5 (22%) 
0 (0%) 
1 (43%) 
3 (13%) 
17 (78%) 
8 (35%) 
20 (87%) 
17 (74%) 
4 (17%) 
3 (13%) 
4 (17%) 
3 (23%) 
4 (17%) 
5 (21%) 
5 (22%) 
 
 
19 (84%) 
4 (17%) 
 
 
14 (61%) 
3 (13%) 
3 (13%) 
3 (13%) 
 
 
3 (13%) 
7 (30%) 
10 (43%) 
3 (13%) 
 
 
 
19 (84%) 
4 (17%) 
 
23 (92%) 
20 (87%) 
2 (7%) 
14 (61%) 
 
 
23 (100%) 
23 (100%) 
0 (0%) 
 
19 (83%) 
 
24 (96%) 
5 (20%) 
0 (0%) 
0 (0%) 
4 (16%) 
22 (88%) 
4 (16%) 
25 (88%) 
20 (80%) 
2 (8%) 
1 (4%) 
2 (3%) 
2 (8%) 
2 (8%) 
4 (16%) 
4 (16%) 
 
 
20 (80%) 
5 (20%) 
 
 
17(68%) 
4 (16%) 
2 (8%) 
2 (8%) 
 
 
2 (8%) 
6 (24%) 
14 (56%) 
3 (4%) 
 
 
 
22 (85%) 
3 (15%) 
 
24 (96%) 
23 (92%) 
4 (16%) 
14 (56%) 
 
 
25 (100%) 
24 (96%) 
1 (4%) 
 
20 (80%) 
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Table 8. Mean high-sensitivity Troponin T at various time points and calculated 
Total Area-under-the-curve at 72 hours post-operatively 
 
 
Time endpoint 
 
 
Control 
(n=23) 
Mean SD 
hsTnT 
(ug/L) 
RIPC (n=25) 
Mean SD 
hsTnT (ug/L) 
Difference 
(95% CI) 
P value 
Pre-operatively 0.020 (0.022) 0.048 (0.163) -0.0969 to 0.0411 0.417 
6 hours 0.643 (0.348) 0.520 (0.276) -0.0569 to 0.3070 0.178 
12 hours 0.604 (0.309) 0.447 (0.214) 0.0036 to 0.3103 0.050 
24 hours 0.392 (0.279) 0.309 (0.154) -0.0465 to 0.2125 0.207 
48 hours 0.340 (0.290) 0.223 (0.105) -0.0077 to 0.2417 0.069 
72 hours 0.334 (0.245) 0.172 (0.111) 0.0535 to 0.2716 0.007 
Total AUC 72 
hours 
28.38 (17.44) 20.07 (9.28) 0.2852 to 16.334 0.050 
 
 
4.1.2 RIPC reduced periprocedural myocardial infarction in a cohort of 
diabetic patients undergoing cardiac surgery. 
 
Two cycles of multi-limb RIPC reduced peri-operative myocardial infarction 
with total area-under-the-curve at 72 hours for HsTnT levels from 28.38 ug/L 
to 20.07 ug/L (p=0.050). This study therefore just achieved significance. 
Notably two individual time points for mean troponin levels also achieved 
significance at 12 hours and 72 hours with p values of 0.050 and 0.007 
respectively. 
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Fig. 4.2. Mean high-sensitivity Troponin T levels at 0, 6, 12, 24, 48 and 72 hours 
in diabetic patients undergoing cardiac surgery (mean±SEM*) 
 
 
 
 
 
 
 
Figure 4.3 Calculated total AUC at 72 hours post-operatively in diabetic 
patients undergoing cardiac surgery and randomised to either sham or two 
cycles of 5 minutes of upper and lower limb ischaemia and reperfusion 
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4.2 Secondary Outcomes 
 
4.2.1 Post-operative Acute Kidney Injury (AKI)  
The amount of acute kidney injury using the scoring system outlined above 
was similar between both groups and did not show statistical significance 
(p=0.8673) 
 
Table 9. AKI scores in diabetic patients undergoing cardiac surgery and 
randomised to either sham or two cycles of 5 minutes of upper and lower limb 
ischaemia and reperfusion 
 
AKI score Control n=23 RIPC n=25 P value 
1 2 2  
2 2 1  
3 1 2  
Totals (%) and SD 5 (22%)  0.421 5 (20%)  0.408 p=0.8673 
 
 
4.2.2 Post-operative atrial fibrillation 
There were 3 cases out of 23 in the control group (13%) and 5 cases out of 25 
in the RIPC group (20%). This was not statistically significant p=0.525 
 
4.2.3 Length of ICU stay and hospital discharge 
The average length of stay in the control group was 2.1 days and the average 
length of stay in the RIC group was 2.4 days. This did not achieve statistical 
significance p=0.763. 
 
The total length of hospital stay was 8.5 days in the control group and 7.8 
days in the RIC group. This did not achieve statistical significance p=0.485. 
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4.2.5 Inotrope score  
The inotrope scores were calculated for 72 hours after coming off bypass in 
both groups. The control group had an inotrope score total of 8.8. and the 
RIPC group had a score of 9.1. This was not statistically significant p=0.928. 
 
4.3 Discussion 
This study of 48 patients showed that an increased stimulus of two cycles of 5 
minutes multi-limb RIPC with two intervening cycles of reperfusion 
cardioprotected diabetic cardiac surgery patients when compared to control 
patients. This increased stimulus showed benefit over a previous study from 
our institution which showed that 3 cycles of 5 minutes single-limb RIPC with 
intervening cycles of reperfusion did not cardioprotect in diabetics. Statistical 
significance was achieved for the primary outcome which showed that 
troponin area-under-the-curve at 72 hours was reduced to 20.07 ug/L with the 
control value being 28.38 ug/L [CI 0.2852 to 16.334, p=0.050] which 
represented a 29% reduction. Statistical significance was also achieved for 
the mean troponin values taken at two time points. These were the 12 hour 
time point mean troponin value with the RIPC value being 0.447 ug/L vs 0.604 
ug/L in the control group [CI 0.0035 to 0.3103, p=0.050] and also the 72 hour 
time point troponin value with the mean RIPC troponin value being 0.172 ug/L 
with the control value being 0.334 ug/L [CI 0.0535 to 0.2716, p=0.007] 
 
It is known that diabetic hearts are less well protected by preconditioning as 
the myocardium behaves differently to towards IR injury. From animal studies 
in diabetic rats preconditioning with a standard ischaemia stimulus fails to 
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demonstrate the reduction in infarction. Studies have shown that a prolonged 
ischaemic stimulus is needed to protect animal diabetic hearts in these 
models (216, 217). We have demonstrated that this increased RIPC stimulus 
overcomes this normally attenuated effect seen in diabetic patients.  
 
Clinical studies have had discrepant results regarding RIPC with diabetic and 
non-diabetic patients but there are no other studies looking at this intervention 
in just diabetic patients. Literature search shows that 7 randomised control 
trials excluded diabetic patients (218-224) completely with 10 randomised 
control trials including both diabetic and non-diabetic patients (225-234). This 
is therefore the first study that shows that an enhanced stimulus 
cardioprotects in diabetic patients. Notably in our study, we excluded patients 
taking the sulphonylurea glibenclamide, which has been demonstrated to 
interfere with IPC, induced cardioprotection by blocking K-ATP channels in 
animal (235, 236) and human models (237,238). The only other sulphonylurea 
used was gliclazide, which does not abrogate the effect of IPC. 
Unfortunately, no statistically significant effect was seen in the secondary 
outcomes of post-operative atrial fibrillation, post-operative acute kidney 
injury, inotrope score and intensive care and hospital stay. The most likely 
explanation for this being that the study is underpowered to show a benefit in 
these outcomes and further recruitment may make differences between the 
two groups more apparent. Another reason is that the time of my study there 
was competing recruitment from the multicentre ERICCA study and then later 
the ERIC-GTN study and so achieving statistical significance was challenged 
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by this as higher risk patients such as those that had poor left ventricular 
function and concomitant valve surgery were preferentially recruited into these 
studies. These groups of higher risk patients should exhibit a more profound 
cardioprotective effect from preconditioning which may also have contributed 
towards achieving statistical significance. Despite this the primary outcome 
has been achieved which shows that an enhanced RIPC stimulus is 
potentially able to overcome the higher preconditioning threshold required in 
order to achieve significant cardioprotection as measured by troponin release. 
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Chapter 5. Results for all-comers undergoing cardiac surgery 
and then post-hoc analysis for patients that received 
intravenous GTN 
 
5.1 Introduction 
5.1.1 A study of RIPC in cardiac bypass patients with or without GTN in 
our institution 
A retrospective analysis of 178 patient cohort suggested that those patients 
receiving IV GTN were not cardioprotected by two cycles of 5 minutes 
ischaemia and 5 minutes reperfusion in simultaneous arm and legs RIPC. 118 
patients received GTN intra-operatively and had been randomised to control 
(n=65) or RIPC (n=53). Baseline characteristics were similar between both 
groups as were the intra-operative parameters. HsTnT levels were lower in 
the RIPC group at all post-operative time-points, however, with a statistical 
significance only at 72 hours. RIPC reduced total AUC at 72 hours when 
compared to control (26.69 ± 13.93 ug/L vs 30.81±17.56 ug/L respectively). 
Although there was trend to cardioprotection in this group this was not 
statistically significant p=0.179. Similarly, there was no significant difference 
between any of the major secondary endpoints although detailed statistical 
analysis showed that there was a significantly improved urine output at 24 and 
72 hours post-operatively and as a total amount over the three days post-
surgery. There was therefore no difference between AKI scores which were 
identical at 5 between both groups, inotrope score which totaled 30.28 in the 
control group at 72 hours and 25.70 in the RIPC group (p=0.663), new onset 
atrial fibrillation which was identical between both groups at 3 new cases 
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(p=0.661), length of ICU stay which was 2.0 days in both groups, length of 
hospital stay (9 days control group vs 8 days in RIPC group, p=0.068). 
 
By increasing the stimulus for RIPC to three cycles of the same protocol we 
hoped to see whether this will result in cardioprotection in those patients 
receiving IV GTN intra-operatively. Use of IV GTN for cardiac surgery in our 
institution is common with up to 83% of patients receiving this intra-
operatively. Its use is primarily dependent on the attending anaesthetist but is 
ubiquitous because of its rapid hypotensive effect and reduction in preload 
through vasodilatation. 
 
Therefore, to study patients that had received this drug we initially recruited 
cardiac surgery all-comers and analysed the data in this cohort. As IV GTN 
use was dependent on the anaesthetist and clinical need, we then performed 
a post-hoc analysis of those patients that had received IV GTN intra-
operatively. 
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Figure 5.1. Study profile for all-comers undergoing cardiac surgery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
Total number of patients screened 173 
 
3 patients refused consent  
 
 
 
 
 4 patients had an eGFR <30ml/min.1.73m2 
 
9 patients excluded as 0 and 72 hour timepoint values missing 
 
87 patients recruited for other studies 
79 patients randomised 
6 patients excluded as more than 3 timepoint values missing missing 
 
44 patients randomised to control and 45 patients randomised to RIPC  
30 patients randomised to RIPC 
 
34 patients control 
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Table 10. Baseline characteristics in patients undergoing cardiac surgery and 
randomised to either sham or three cycles of 5 minutes of upper and lower 
limb ischaemia and reperfusion 
 
Patient Characteristic Control (n=34) 
  
  RIPC (n=30) 
   
 
Age (years) 
Gender  
Male 
Female 
 
Ethnicity 
Caucasian 
Asian 
Turkic 
Middle-Eastern 
 
Body Mass Index 
 
Smoking history 
Smoker 
Ex-smoker 
Non-smoker 
 
Co-morbidities 
Diabetes Mellitus 
Hypertension 
Hypercholesterolaemia 
Atrial Fibrillation 
Previous MI 
Previous CVA/TIA 
Previous cardiac surgery 
 
LVEF 
>50% 
30-50% 
<30% 
 
NYHA 
 
CCS 
 
Family History of 
ischaemic heart disease 
 
Euroscore 
 
Bypass time (mins) 
 
Cross-clamp time (mins) 
 
67±10 
 
25 (74%) 
9 (26%) 
 
 
23 (68%) 
8 (23%) 
2 (6%) 
1 (3%) 
 
30.1±5.5 
 
 
6 (18%) 
18 (53%) 
10 (30%) 
 
 
8 (24%) 
28 (82%) 
27 (79%) 
2 (6%) 
12 (35%) 
1 (3%) 
0 
 
 
32 (94%) 
2 (6%) 
0 
 
2.3±0.8 
 
2.8±0.9 
 
20 (58%) 
 
 
3.62±1.99 
 
92.3±28.7 
 
61±27.8 
 
69±9 
 
20 (67%) 
10 (33%) 
 
 
18 (60%) 
9 (30%) 
1 (3%) 
2 (7%) 
 
28±4.4 
 
 
8 (27%) 
15 (50%) 
7 (23%) 
 
 
8 (28%) 
22 (73%) 
22 (73%) 
3 (10%) 
8 (27%) 
2 (6%) 
0 
 
 
27 (90%) 
3 (10%) 
0 
 
2.4±0.8 
 
2.9±0.8 
 
22 (73%) 
 
 
3.88±2.01 
 
88.9±31.8 
 
64.4±22.2 
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Patient Characteristic Control (n=34)   RIPC (n=30) 
Drug history 
Aspirin 
Clopidogrel 
Prasugrel 
Ticagrelor 
Warfarin 
Beta-blocker 
Calcium channel blocker 
Statin 
Ace-i/A2RB 
Long acting nitrate 
Nicorandil 
Insulin 
Biguanide 
Sulphonylurea 
Thiazolidinediones 
Diuretics 
 
Cardioprotection 
Blood cardioplegia 
Cross-clamp fibrillation 
 
Operation 
CABG 
AVR 
MVR or repair 
CABG+AVR 
 
Grafts 
1 
2 
3 
4 
 
Anaesthetic agents 
Induction 
Rocuronium 
Pancuronium 
 
Propofol 
Fentanyl 
Etomidate 
Midazolam 
 
Maintenance 
Propofol 
Isoflurane 
Sevoflurane 
 
Intra-operative Glyceryl 
trinitrate 
 
31 (91%) 
8 (21%) 
1 (3%) 
3 (10%) 
4 (12%) 
22 (73%) 
8 (24%) 
28 (93%) 
22 (73%) 
5 (15%) 
3 (9%) 
2 (6%) 
7 (21%) 
5 (15%) 
2 (7%) 
8 (24%) 
 
 
28 (82%) 
6 (18%) 
 
 
19 (74%) 
5 (14%) 
4 (12%) 
0 (0%) 
 
 
2 (6%) 
10 (29%) 
15 (44%) 
7 (21%) 
 
 
 
28 (82%) 
6 (18%) 
 
32 (94%) 
28 (82%) 
3 (9%) 
15 (44%) 
 
 
34 (100%) 
32 (94%) 
2 (6%) 
 
22 (73%) 
 
26 (87%) 
7 (23%) 
0 (0%) 
1 (3%) 
5 (17%) 
25 (83%) 
5 (16%) 
25 (83%) 
20 (67%) 
6 (20%) 
2 (7%) 
4 (13%) 
4 (13%) 
6 (20%) 
1 (3%) 
6 (20%) 
 
 
25 (83%) 
5 (17%) 
 
 
23 (77%) 
4 (15%) 
3 (10%) 
0 (0%) 
 
 
1 (3%) 
10 (33%) 
15 (50%) 
4 (13%) 
 
 
 
26 (87%) 
4 (13%) 
 
26 (87%) 
27 (90%) 
4 (13%) 
15 (50%) 
 
 
30 (100%) 
28 (97%) 
2 (3%) 
 
25 (83%) 
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5.1.2 RIPC did not reduce periprocedural myocardial infarction in an 
unselected cohort of patients undergoing cardiac surgery. 
 
Although there was only a single time point of troponin taken at 24 hours that 
achieved statistical significance, the RIPC group had a mean value of 
troponins that were lower at each time point. As well as this, the 72 hour 
troponin AUC was also lower in value in the RIPC group, and approached 
statistical significance but did not achieve it between the two groups 
(p=0.074).  
 
Table 11. Mean high-sensitivity Troponin T at various time points and 
calculated Total Area-under-the-curve at 72 hours post-operatively 
 
Time endpoint Control (n=34) 
Mean SD 
hsTnT (ug/L) 
RIPC (n=30) 
Mean SD 
hsTnT (ug/L) 
Difference 
(95% CI) 
P value 
Pre-operatively 0.014 (0.019) 0.018 (0.016) -0.0795 to 0.0715 0.841 
6 hours 0.669 (0.338) 0.512 (0.275) -0.0128 to 0.0048  0.364 
12 hours 0.620 (0.324) 0.413 (0.244) 0.0017 to 0.3122 0.047 
24 hours 0.498 (0.423) 0.314 (0.181) 0.0621 to 0.3518 0.058 
48 hours 0.453 (0.498) 0.308 (0.196) -0.0489 to 0.3338 0.140 
72 hours 0.402 (0.421) 0.260 (0.118) -0.0170 to 0.3010 0.071 
Total AUC 72 
hours 
34.29 (25.26) 23.00 (20.23) -1.145 to 23.723 0.074 
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Figure 5.2 Mean high-sensitivity Troponin T levels at various time points in 
patients undergoing cardiac surgery (meanSEM) 
 
 
 
 
 
Figure 5.3. Calculated total AUC at 72 hours post-operatively in patients 
undergoing cardiac surgery and randomised to either sham or three cycles of 5 
minutes of upper and lower limb ischaemia and reperfusion 
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5.2 Secondary Outcomes 
5.2.1 Post-operative Acute Kidney Injury (AKI)  
The amount of acute kidney injury using the scoring system outlined above 
was similar between both groups and did not show statistical significance 
(p=0.7186) 
 
Table 12. AKI scores in patients undergoing cardiac surgery and randomised 
to either sham or three cycles of 5 minutes of upper and lower limb ischaemia 
and reperfusion 
 
AKI score Control n=34 RIPC n=30 P value 
1 2 3  
2 1 0  
3 0 1  
Totals (%) and SD 3 (8.8%)  0.404 4 (13.3%)  0.584 p=0.7186 
 
 
5.2.2 Post-operative atrial fibrillation 
There were 5 cases out of 34 in the control group (14.7%) and 3 cases out of 
30 in the RIPC group (10%). This was not statistically significant p=0.5722. 
 
5.2.3 Length of ICU stay and hospital discharge 
The average length of stay in the control group was 2.3 days and the average 
length of stay in the RIC group was 2.0 days. This did not achieve statistical 
significance p=0.662. 
 
The total length of hospital stay was 7.5 days in the control group and 8.1 
days in the RIC group. This did not achieve statistical significance p=0.535. 
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5.2.4 Inotrope score  
The inotrope scores were calculated for 72 hours after coming off bypass in 
both groups. The control group had an inotrope score total of 8.1 and the 
RIPC group had a score of 11.8. This was not statistically significant p=0.278. 
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5.3 Post-hoc analysis of patients that received intravenous GTN 
 
Table 13. Baseline characteristics in patients undergoing cardiac surgery that 
had received intravenous GTN and randomised to either sham or three cycles 
of 5 minutes of upper and lower limb ischaemia and reperfusion 
 
Patient Characteristic Control (n=22) 
  
  RIPC (n=25) 
  
 
Age (years) 
Gender  
Male 
Female 
 
Ethnicity 
Caucasian 
Asian 
Turkic 
Middle-Eastern 
 
Body Mass Index 
 
Smoking history 
Smoker 
Ex-smoker 
Non-smoker 
 
Co-morbidities 
Diabetes Mellitus 
Hypertension 
Hypercholesterolaemia 
Atrial Fibrillation 
Previous MI 
Previous CVA/TIA 
Previous cardiac surgery 
 
LVEF 
>50% 
30-50% 
<30% 
 
NYHA 
 
CCS 
 
Family History of IHD 
 
Euroscore 
 
Bypass time (mins) 
 
Cross-clamp time (mins) 
 
65±9 
 
18 (82%) 
  4 (18%) 
 
 
16 (73%) 
 5 (23%) 
 1 (5%) 
 0 (0%) 
 
30.8±5.1 
 
 
4 (18%) 
12 (55%) 
6 (27%) 
 
 
3 (14%) 
16 (73%) 
15 (68%) 
1 (5%) 
8 (36%) 
1 (3%) 
0 
 
 
21 (95%) 
1 (5%) 
0 
 
2.2±0.6 
 
2.7±0.8 
 
14 (64%) 
 
3.58±1.89 
 
90.6±25.7 
 
58±25.9 
 
71±8 
 
17 (68%) 
8 (32%) 
 
 
14 (56%) 
 5 (20%) 
 0 (0%) 
 2 (8%) 
 
29.2±4.9 
 
 
4 (16%) 
12 (48%) 
9 (36%) 
 
 
6 (24%) 
16 (64%) 
17 (77%) 
1 (4%) 
3 (12%) 
2 (8%) 
0 
 
 
23 (92%) 
 2 (8%) 
0 
 
2.4±0.7 
 
2.8±0.7 
 
20 (80%) 
 
3.92±2.05 
 
85.9±35.8 
 
66.3±25.2 
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Patient Characteristic Control (n=22)   RIPC (n=25) 
Drug history 
Aspirin 
Clopidogrel 
Prasugrel 
Ticagrelor 
Warfarin 
Beta-blocker 
Calcium channel blocker 
Statin 
Ace-i/A2RB 
Long acting nitrate 
Nicorandil 
Insulin 
Biguanide 
Sulphonylurea 
Thiazolidinediones 
Diuretics 
 
Cardioprotection 
Blood cardioplegia 
Cross-clamp fibrillation 
 
Operation 
CABG 
AVR 
MVR or repair 
CABG+AVR 
 
Grafts 
1 
2 
3 
4 
 
Anaesthetic agents 
Induction 
Rocuronium 
Pancuronium 
 
Propofol 
Fentanyl 
Etomidate 
Midazolam 
 
Maintenance 
Propofol 
Isoflurane 
Sevoflurane 
 
Intra-operative Glyceryl 
trinitrate 
 
20 (91%) 
4 (18%) 
0 (0%) 
1 (5%) 
1 (5%) 
18 (82%) 
6 (27%) 
20 (91%) 
17 (77%) 
3 (14%) 
2 (9%) 
2 (9%) 
5 (23%) 
3 (13%) 
2 (9%) 
6 (27%) 
 
 
20 (91%) 
2 (19%) 
 
 
17 (77%) 
3 (14%) 
2 (9%) 
0 (0%) 
 
 
2 (6%) 
10 (29%) 
15 (44%) 
7 (21%) 
 
 
 
28 (82%) 
6 (18%) 
 
32 (94%) 
28 (82%) 
3 (9%) 
15 (44%) 
 
 
22 (100%) 
20 (91%) 
2 (9%) 
 
22 (100%) 
 
20 (80%) 
5 (20%) 
0 (0%) 
0 (0%) 
3 (12%) 
20 (80%) 
4 (18%) 
21 (84%) 
18 (72%) 
3 (12%) 
0 (0%) 
2 (8%) 
3 (12%) 
6 (24%) 
1 (3%) 
4 (16%) 
 
 
20 (80%) 
5 (20%) 
 
 
18 (72%) 
5 (20%) 
2 (8%) 
0 (16%) 
 
 
1 (3%) 
10 (33%) 
15 (50%) 
4 (13%) 
 
 
 
26 (87%) 
4 (13%) 
 
26 (87%) 
27 (90%) 
4 (13%) 
15 (50%) 
 
 
25 (100%) 
23 (92%) 
2 (8%) 
 
25 (100%) 
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Table 14. mean  high-sensitivity Troponin T at various time points and 
calculated Total Area-under-the-curve at 72 hours post-operatively 
 
 
 
 
5.3.1 RIPC did not reduce periprocedural myocardial infarction in a 
retrospective analysis of patients undergoing cardiac surgery that had 
received intravenous GTN. 
 
 
No single time point of troponin taken achieved statistical significance 
although they were all lower in the RIPC group. Although the RIPC group had 
a mean value of troponins that were lower and the 72 hour troponin AUC was 
also lower in value this did not achieve statistical significance between the two 
groups (p=0.194).  
 
 
 
 
 
 
 
 
Time endpoint Control (n=22) 
Mean SD 
hsTnT (ug/L) 
RIPC (n=25) 
Mean SD 
hsTnT (ug/L) 
Difference 
(95% CI) 
P value 
Pre-operatively 0.015 (0.032) 0.012 (0.008) -0.0111 to 0.0158 0.732 
6 hours 0.589 (0.348) 0.419 (0.133) 0.0180 to 0.3210 0.028 
12 hours 0.559 (0.320) 0.399 (0.258) -0.0099 to 0.3299 0.064 
24 hours 0.403 (0.204) 0.308 (0.188) -0.0201 to 0.2101 0.103 
48 hours 0.289 (0.575) 0.260 (0.229) -0.0222 to 0.280 0.817 
72 hours 0.220 (0.201) 0.209 (0.166) -0.096 to 0.1100 0.830 
Total AUC 72 
hours 
25.44 (18.34) 19.52 (12.24) -3.1404 to 14.982 0.194 
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Figure 5.4. Mean high-sensitivity Troponin T levels at various time points in 
patients undergoing cardiac surgery (meanSEM) 
 
 
 
 
 
 
 
Figure 5.5. Calculated total AUC at 72 hours post-operatively in patients 
undergoing cardiac surgery and randomised to either sham or three cycles of 5 
minutes of upper and lower limb ischaemia and reperfusion 
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5.4 Secondary Outcomes 
5.4.1 Post-operative Acute Kidney Injury (AKI)  
The amount of acute kidney injury using the scoring system outlined above 
was similar between both groups and did not show statistical significance 
(p=0.7186) 
 
Table 15. AKI scores in patients undergoing cardiac surgery that had received 
intravenous GTN and randomised to either sham or three cycles of 5 minutes 
of upper and lower limb ischaemia and reperfusion 
 
AKI score Control n=22 RIPC n=25 P value 
1 1 2  
2 1 0  
3 0 0  
Totals (%) and SD 2 (5.9%)  0.236 2 (6.7%)  0.638 p=0.956 
 
 
5.4.2 Post-operative atrial fibrillation in patients receiving intravenous 
GTN 
There were 3 cases out of 22 in the control group (13.6%) and 2 cases out of 
25 in the RIPC group (8%). This was not statistically significant p=0.522. 
 
 
5.4.3 Length of ICU stay and hospital discharge in patients receiving 
intravenous GTN. 
 
The average length of stay in the control group was 2.2 days and the average 
length of stay in the RIC group was 2.1 days. This did not achieve statistical 
significance p=0.862. 
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The total length of hospital stay was 7.3 days in the control group and 7.9 
days in the RIC group. This did not achieve statistical significance p=0.431. 
 
5.4.4 Inotrope score in patients receiving intravenous GTN 
The inotrope scores were calculated for 72 hours after coming off bypass in 
both groups. The control group had an inotrope score total of 7.8 and the 
RIPC group had a score of 11.1. This was not statistically significant p=0.322. 
 
5.5 Discussion 
The results from this study show that although there was a trend towards 
RIPC resulting in cardioprotection in cardiac surgery in the presence of GTN 
there was no statistically significant reduction in perioperative myocardial 
injury as measured by hsTnT (ug/L) area-under-the-curve at 72 hours. There 
was also no significant reduction in the onset of new acute kidney injury, atrial 
fibrillation, inotrope score, intensive care stay and hospital stay. Similarly, 
there was also a trend to cardioprotection in my subgroup post-hoc analysis of 
those patients that had received intravenous GTN intra-operatively, but this 
did not achieve a statistically significant reduction in perioperative myocardial 
injury. Although the RIPC group had lower mean values of troponins in this 
study, this was not reflected in the total area-under-the-curve at 72 hours. The 
secondary endpoints of new acute kidney injury, atrial fibrillation, inotrope 
score, intensive care stay and hospital stay were not significant.  
 
This study which has the greatest RIPC stimulus afforded to patients and 
consisted of three cycles and 2 limb ischaemia failed to show cardioprotection 
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in all-comers and the post-hoc analysis of those patients receiving IV GTN 
with study size being probably the greatest hindrance here. Another possibility 
is that at the time of my study there was competing recruitment from the 
multicentre ERICCA study and then later the ERIC GTN study and so 
achieving statistical significance was challenged by this as the ERICCA study 
preferentially recruited higher risk patients such as those that had poor left 
ventricular function and concomitant valve surgery. These groups of higher 
risk patients should exhibit a more profound cardioprotective effect from 
preconditioning which may also have contributed towards achieving statistical 
significance. Other problems affecting recruitment included the high number 
of recruited elective patients that were cancelled on the day of surgery, which 
totalled 48%, and this was due to bed pressure. In addition, a significant 
number of patients had to be excluded from my study due to incomplete 
troponin data sets. Difficulties mainly arose from ensuring that blood samples 
were taken and that to in a timely fashion. Other less frequent but important 
problems included blood forms going missing and samples being lost on the 
way to the laboratory. Another important consideration is that missing data 
values were imputed using software, but hopefully the effect of this would be 
minimal as data that had more than two missing time points were excluded. 
Similar problems were seen in the ERICCA trial, which had only 45.2% of 
patients with complete data sets. 
 
Another factor is that it remains unknown what the exact optimal 
preconditioning stimulus is to achieve cardioprotection. Previous studies and 
meta-analyses have shown that three cycles of 5 minutes of upper arm 
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ischaemia provide cardioprotection (239-242). Subsequent to this a shortened 
RIPC protocol but more intense stimulus involving two cycles of upper and 
lower limb ischaemia from a study from our own institution has also shown to 
reduce perioperative myocardial injury. The optimal conditioning protocol for 
RIPC to elicit organ protection in human remains unknown. Only one 
laboratory study from Xin et al (243) found that 3-4, but not 1 to 2 cycles of 5-
minutes ischaemia with 5 minutes (5minutes/5minutes) reperfusion could 
provide additive cardioprotection to local postconditioning, and that similar 
results were obtained in 4 cycles of 3-minutes/3-minutes or 1-minute/1-
minute. How this applies clinically is still unknown.  
 
Although there is a trend towards significance the most likely contributing 
factor as to why that this was not achieved was most likely due to the study 
being underpowered it is also possible that the effect of RIPC is simply not 
pronounced enough to produce a clinically significant result. My results 
therefore typify the spectrum of results seen in preconditioning clinical trials.  
The first clinical trial of RIPC was in the year 2000 with 8 patients undergoing 
cardiac surgery being randomised to forearm cuff ischaemia or control. This 
study showed an increase in lactate dehydrogenase in the RIPC group which 
was attributed to preconditioned cells being able to maintain anaerobic 
metabolism (244). Further studies with positive findings supporting RIPC 
followed in paediatric surgery showing benefit in troponin levels, inotrope 
support and airways resistance at 6 hours (245). Further studies followed from 
our own institution in 2007 and 2009 with studies from Hausenloy et al (246) 
and Venugopal et al (247) showing significant reductions in troponin in cardiac 
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surgery patients undergoing cross-clamp fibrillation and cold blood 
cardioplegia. 
 
However, in 2010 there were conflicting results to previous studies produced 
by the Rahman et al. (248) from Birmingham.  This was the first large, single-
centre double-blind randomised controlled trial with 162 patients undergoing 
CABG randomised to receive either three cycles of 5 minutes of upper limb 
cuff inflation to 200mmHg with 5 minutes of intervening reperfusion or sham 
involving an automated blood pressure cuff placed on a dummy arm under a 
drape. This was to aid in the blinding of staff. This study showed no difference 
in troponin between the two groups or cardiac performance, inotrope 
requirement, echocardiographic function, arrhythmia protection, or renal and 
lung outcomes. Two possible explanations for the negative data from this 
study were that all patient received IV GTN and so perhaps the ischaemic 
stimulus was not great enough to overcome the attenuating effect of this intra-
operative medication. Subsequent to this a study from our own institution 
suggested cardioprotection with a reduction in perioperative myocardial injury 
by 26% and a fall in acute kidney injury by 48% (249). 
 
 The ERICCA study (249) from our own institution and RIPHeart study (250) 
followed on from these and in contrast once again they similarly failed to show 
benefit. These studies were being undertaken at the time of my research and 
the results only available and published sometime after I had finished 
recruitment. These were both huge multicentre, prospective, randomised 
controlled trials of cardiac surgery patients that had been placed on 
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cardiopulmonary bypass. These studies were both large-scale with 1612 and 
1385 patients respectively. Patients were screened and only higher risk 
patients with Euroscores greater than 4.2 and 5 respectively were recruited in 
the hope that this would give adequate room to show benefit. Both studies 
failed to reduce major adverse cardiac and cerebral events with the ERICCA 
study looking at longer term follow up to 12 months. Similar findings 
contrasting previous studies with potentially worrisome findings with 
deleterious outcomes were also seen in other studies (251). The reasons for 
these negative results have been widely discussed and there are many 
potential explanations and confounders. Firstly, it is well described that 
diabetic and infarct remodelled hearts are less well cardioprotected by 
preconditioning. Up to 30% of patients in my study were diabetic which we 
know do not respond to preconditioning and many stable angina patients are 
believed to precondition the heart through repetitive episodes of ischaemia 
which ultimately result in left ventricular remodelling and cardioprotection. It 
has been well described that patients experiencing stable angina up to three 
months prior to acute myocardial infarction have a reduced infarct size (253) 
and so in this cohort of patients any additional effect from RIPC may be 
limited as maximal preconditioning has already occurred. As discussed 
earlier, in diabetic hearts the myocardium behaves differently in relation to IR 
injury and this is felt to be through differences in metabolism or intracellular 
signalling when compared to normal myocardium. Either any effect from RIPC 
is attenuated or to achieve cardioprotection a greater stimulus is needed in 
the diabetic heart. 
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Other factors that may further hinder possible RIPC cardioprotection include 
cardiopulmonary bypass itself through mediation of the inflammatory 
response, cardioplegic solutions and the cooling of patients which both work 
metabolically to protect. The administration of concomitant medications is also 
well known to interfere with RIPC especially anaesthetic agents. Propofol 
which has been used intra-operatively in approaching 100% of patients in my 
studies and the volatile anaesthetics sevoflurane and isoflurane are well 
recognised for their RIPC-attenuating effects. Intravenous GTN which is used 
ubiquitously by anaesthetists for its vasodilating effects to help lower blood 
pressure intra-operatively also plays a similar role with a previous study from 
our institution showing that patients receiving this drug had 39% lower 
perioperative myocardial infarction. This group of patients are cardioprotected 
by the nitrate and it is likely that RIPC is not able to overcome this beneficial 
effect. Even my increased stimulus of three multi-limb cycles failed to show 
benefit in this group. 
 
Another recognised issue in my studies and other trials is the difficulty with 
blinding as anaesthetic staff and surgeons would be aware of whether the 
patients were undergoing intervention with RIPC or sham. Rahman et al 
managed to overcome this with an elaborate sham method which simulated 
the intervention as mentioned above. This should be considered in future 
studies. 
 
This paradigm has been difficult to resolve although what is apparent is that 
there is an effect from RIPC but it cannot be consistently reproduced and 
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central to this is the precise ischaemic dose that needs to be delivered 
remains elusive. My two studies exhibit this with 2 multi-limb cycles 
cardioprotecting diabetic hearts yet 3 multi-limb cycles failing to show 
significant cardioprotection in a cohort that received IV GTN albeit showing a 
trend to reduced periprocedural myocardial infarction. Secondly, there are 
many confounding factors that may interfere with preconditioning pathways or 
may precondition the heart itself to an extent where there is no scope left for 
an additive effect from RIPC.  The ERIC-GTN trial being conducted by our 
own institution hopes to answer some of these questions and elucidate 
whether IV GTN interferes with RIC protection. This trial is ongoing and will be 
discussed in the next chapter.  
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Chapter 6. Future considerations 
As mentioned diabetes is a risk factor for coronary artery disease with several 
postulated mechanisms for the association including abnormal lipid 
metabolism, nitric oxide levels, platelet function, clotting and autonomic 
function. Not only is diabetes a risk factor for coronary disease but 
observational studies show worse outcomes in diabetics undergoing coronary 
artery bypass surgery (254-259). The increased mortality and morbidity 
among diabetics after surgery is felt to be due to the more aggressive nature 
of the atherosclerosis, the diffuse nature of the disease and its effects on the 
distal artery and on the microvasculature. Adverse outcomes are felt to be 
due to native vessel disease progression, graft failure, diabetic myocardium 
and the systemic morbidity associated wth the disease (260,261). Studies 
have also shown that generally CABG is the preferred mode of 
revascularisation in diabetics with multivessel disease and also those that 
have impaired left ventricular function. In patients with diabetes and 
multivessel disease, PCI with a current generation stent is associated with a 
lower risk of death and stroke in early follow-up but a higher rate of 
myocardial infarction and need for repeat revascularization in the long term 
when compared to CABG (262). The Future Revascularization Evaluation in 
patients with Diabetes Mellitus: Optimal Management of Multivessel disease 
(FREEDOM) trial also showed a long-term mortality benefit in CABG patients 
and it is on this basis that the US and Europe recommend CABG over PCI as 
a class I indication (263). In light of this new cardioprotective strategies which 
can help protect diabetic myocardium are needed to improve clinical 
outcomes in diabetic patients with coronary heart disease undergoing CABG. 
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Unfortunately, despite IPC showing potential as a strategy to improve 
outcomes in CABG it appears that in diabetics it faces an even greater 
challenge. However, with further clinical studies to help deepen our 
understanding of cardioprotection this defiant group of patients may 
eventually yield to the benefits of IPC if found. 
 
Intraoperative GTN, which is a nitric oxide (NO) donor, is often used in cardiac 
surgery as already discussed. Preclinical studies have already well 
established the cardioprotective effects of NO but we remain uncertain about 
whether this translates to a benefit in cardiac surgery patients. As discussed, 
a post-hoc analysis from our institution showed that RIPC failed to show 
significant cardioprotection in a group of cardiac surgery patients that received 
IV GTN and when RIPC was compared to a control group.  Further post-hoc 
analysis of those patients in the control group that were administered intra-
operative IV GTN during cardiac surgery showed that total 72 hours AUC 
hsTnT was reduced by 39% in those control patients who had been 
administered intraoperative IV GTN compared with those control patients that 
had not (30.8±17.6ug/L vs 50.5±34.2ug/L, p<0.001). To help gain further 
understanding and potentially answer these questions a study from our own 
institution is now being conducted looking into this which is a prospective 
designed randomized clinical trial (ERIC-GTN) mentioned above. The ERIC-
GTN trial is a single-site, double-blind, randomised, placebo-controlled study 
looking at cardiac surgery patients. This study hopes to recruit 260 patients 
randomised to one of four treatment groups following anaesthetic induction. 
The groups are (1) RIC alone, a RIC protocol comprising three 5-minute 
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cycles of simultaneous upper-arm and thigh cuff inflation/deflation followed by 
an intravenous (IV) placebo infusion; (2) GTN alone, a simulated sham RIC 
protocol followed by an IV GTN infusion; (3) RIC + GTN, a RIC protocol 
followed by an IV GTN infusion; and (4) neither RIC nor GTN, a sham RIC 
protocol followed by IV placebo infusion. The ERIC-GTN trial should help 
determine whether intraoperative GTN therapy is cardioprotective during 
cardiac surgery and whether it affects RIC cardioprotection (264). The four 
arms should also be able to help answer whether RIC may be unable to 
confer additional cardioprotection over that provided by GTN itself or whether 
it was due to GTN reducing RIC cardioprotection. 
 
Interestingly a very recent meta-analysis published in February 2017 of 5262 
patients from all studies undergoing RIPC for cardiac surgery with 
cardiopulmonary bypass these inconsistent findings were all echoed with 
intervention failing to show reduced incidence of all-cause mortality, 
myocardial infarction, stroke, and lengths of ITU and hospital stay (265). 
Despite this, there was a strong trend towards reduction in AKI in patients that 
had not received propofol. In the subgroup of studies of patients who did not 
receive propofol which was not many as this is a very commonly used intra-
operative drug to maintain anaesthesia, they observed that there were slightly 
more male patients (60.3%) and the mean or median age ranged from 57.0 to 
70.6 years so very similar to baseline characteristics seen in studies from our 
institution. In this subgroup who did not receive propofol, 71 of 217 patients 
(32.7%) who underwent RIPC developed AKI compared with 103 of 217 
patients (47.5%) treated with a sham procedure. The RR of RIPC versus 
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sham for AKI was 0.700 and significant statistically (95% CI, 0.527–0.930; 
p=0.014). Interestingly, studies of patients who had been given propofol 
showed that of 445 of 1874 patients (23.7%) who received RIPC developed 
AKI compared with 474 of 1901 (24.9%) who underwent a sham procedure 
which was not statistically significant (p=0.14). This meta-analysis strongly 
suggests that future cardiac studies should be performed in the absence of 
propofol. 
 
Due to these inconsistent results in cardiac surgery and essentially stable 
patients, RIPC has been used to explore whether it can reduce cardiac and 
renal events in patients that are unstable. The rationale for this being that the 
magnitude of ischaemia in a stable patient is not significant enough for RIPC 
to show a beneficial effect and so current studies are looking at whether acute 
ST elevation myocardial infarction patients may be the correct substrate. The 
foundation for this has been laid down in the two studies that are ERIC-LYSIS 
(Effect of Remote Ischaemic Conditioning in STEMI patients treated by 
thromboLYSIS) (266) and CONDI (effect of RIC on clinical outcomes in 
STEMI patients undergoing pPCI) (267). ERIC-LYSIS randomised STEMI 
patients to receive thrombolysis with or without Remote ischaemic per-
conditioning RIPerC and CONDI randomised STEMI patients to receive 
primary percutaneous coronary intervention (PPCI) with or without in-
ambulance RIPerC. Eric lysis showed a median reduction in troponin by 32% 
troponin T (p=0.020) with RIPerC while CONDI showed a significant reduction 
in all-cause mortality (p=0.027) at follow up for a median for 3.8 years.  
 
117 
 
As a consequence of these two proof-of concept studies there are currently 
two studies underway with results due in 18 months which are the CONDI 2 
(Effect of RIC on Clinical Outcomes in STEMI Patients undergoing pPCI) and 
ERIC-PPCI (Effect of Remote Ischaemic Conditioning in Clinical Outcomes in 
STEMI Patients Undergoing PPCI) (268).  Although the initial ERIC-LYSIS 
study looked at thrombolysis patients this treatment for acute myocardial 
infarction has been superseded by PPCI worldwide. Together these studies 
will recruit around 4300 patients and are both multi-centre, multi-national, 
double-blinded RCTs. Primary endpoints of hospitalisation for heart failure or 
cardiovascular mortality at one year will give a definitive answer to this 
promising area for conditioning. Hopefully, this cheap and easy-to-apply 
intervention will finally be able to modulate reperfusion injury and affect infarct 
size so that there can be clinically significant reductions in cardiovascular 
outcomes.  
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